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ABSTRACT OF THE DISSERTATION 
COVALENT PROTEIN ADDUCTION OF NITROGEN MUSTARDS AND RELATED 
COMPOUNDS 
by 
Vanessa Thompson 
Florida International University, 2014 
Miami, Florida 
Professor Anthony DeCaprio, Major Professor 
Chemical warfare agents continue to pose a global threat despite the efforts of the 
international community to prohibit their use in warfare. For this reason, improvement in the 
detection of these compounds remains of forensic interest. Protein adducts formed by the covalent 
modification of an electrophilic xenobiotic and a nucleophilic amino acid may provide a 
biomarker of exposure that is stable and specific to compounds of interest (such as chemical 
warfare agents), and have the capability to extend the window of detection further than the parent 
compound or circulating metabolites. 
This research investigated the formation of protein adducts of the nitrogen mustard 
chemical warfare agents mechlorethamine (HN-2) and tris(2-chloroethyl)amine (HN-3) to lysine 
and histidine residues found on the blood proteins hemoglobin and human serum albumin. 
Identified adducts were assessed for reproducibility and stability both in model peptide and whole 
protein assays. Specificity of these identified adducts was assessed using in vitro assays to 
metabolize common therapeutic drugs containing nitrogen mustard moieties. Results of the model 
peptide assays demonstrated that HN-2 and HN-3 were able to form stable adducts with lysine 
and histidine residues under physiological conditions. Results for whole protein assays identified 
three histidine adducts on hemoglobin, and three adducts (two lysine residues and one histidine 
residue) on human serum albumin that were previously unknown. These protein adducts were 
vii 
determined to be reproducible and stable at physiological conditions over a three-week analysis 
period. Results from the in vitro metabolic assays revealed that adducts formed by HN-2 and HN-
3 are specific to these agents, as metabolized therapeutic drugs (chlorambucil, cyclophosphamide, 
and melphalan) did not form the same adducts on lysine or histidine residues as the previously 
identified adducts formed by HN-2 and HN-3. Results obtained from the model peptide and full 
protein work were enhanced by comparing experimental data to theoretical calculations for 
adduct formation, providing further confirmatory data. This project was successful in identifying 
and characterizing biomarkers of exposure to HN-2 and HN-3 that are specific and stable and 
which have the potential to be used for the forensic determination of exposure to these dangerous 
agents. 
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1. INTRODUCTION 
The history of chemical and biological warfare agents can be traced back thousands of 
years. Since World War I, the advancement of chemical weapons has been quite drastic, and 
despite the efforts of the international community to ban the use of these chemicals during 
warfare, they are still utilized today. For this reason, it is important for the forensic community to 
develop methods for their detection not only in environmental samples, but in human specimens 
as well. Two challenges to the detection and identification of these compounds in biological 
materials involve the limited time in which the parent compounds are present in the blood and the 
low specificity of circulating metabolites. As such, a different approach to their detection is 
necessary. Protein adduction by reactive xenobiotics, including chemical weapons, may provide a 
method for exposure determination that is not only specific to the compound of interest, but also 
provides a longer lasting exposure biomarker as compared to the parent compound or metabolites. 
The current research was performed to identify and characterize potential protein adduct 
biomarkers of exposure to the Schedule I chemical warfare agent nitrogen mustards 
mechlorethamine (HN-2) and tris(2-chloroethyl)amine (HN-3) to lysine and histidine residues on 
the blood proteins hemoglobin and serum albumin using liquid chromatography tandem mass 
spectrometry. Identified adducts were assessed for their specificity as HN-2 and HN-3 exposure 
markers as compared to other compounds containing nitrogen mustard moieties, including 
ethanolamine precursor compounds and alkylating cancer drugs. Adducts were also assessed for 
their stability at physiological conditions (37°C, pH 7.4), which would lend confidence to the use 
of identified adducts as potential biomarkers of exposure for nitrogen mustard chemical weapons. 
This research has not only filled an important gap in nitrogen mustard protein adduction research, 
but has also provided evidence for additional avenues of adduction exploration for these 
forensically important compounds.
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2. LITERATURE REVIEW 
2.1. Chemical Warfare Agents 
Chemical warfare agents (CWA) are defined as chemicals that are used to incapacitate, 
injure, or kill an individual or group of individuals.1 The use of chemical weapons in some form 
or fashion can be traced back to ancient times, when armies would use toxic or incapacitating 
chemicals (such as sulfur) along with biological agents (such as poisonous plants or animals) to 
kill or make enemies sick.2 The first large-scale use of chemical weapons during wartime 
occurred in World War I (WWI), where chlorine gas was released by German forces at Ypres.2  
This, along with other instances in WWI in which other chemical weapons were utilized 
(including phosgene, sulfur mustard, and cyanide), marked a time of importance for chemical 
weapons research. In the ensuing years, several advances were made in the CWA field, including 
the use and development of sulfur mustard (HD) in 1917 and the organophosphate nerve agents in 
the 1930s.2  
Parallel with the development and “improvement” of these chemical weapons were 
attempts by the international community to prohibit the use of both chemical and biological 
agents during wartime because of their potentially devastating effects. The most recent attempt at 
control of these compounds occurred when the Organization for the Prohibition of Chemical 
Weapons (OPCW) was formed. The committee drafted the Chemical Weapons Convention 
(CWC), which was signed by several countries throughout the world (including the United States) 
in 1993. The CWC detailed the prohibition of the use and stockpiling of chemical weapons, in 
addition to providing a scheduling process for these compounds for those countries that ratified 
the treaty. To date, 189 countries have signed the treaty and ratified it into law. Two states (Israel 
and Myanmar) have signed the treaty, but have yet to implement its mandate. Four states 
(Angola, Egypt, North Korea, and South Sudan) have not signed the treaty.3 Despite these 
measures, however, chemical weapons are still a threat, with recent use by both radical cults and 
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militant governments. For example, in 1995 the Japanese cult group Aum Shinrikyo was 
responsible for the release of sarin, an organophosphate nerve agent, in the city of Matsumoto and 
on a Tokyo subway in 1994 and 1995, respectively.4 Most recently, the Assad regime in Syria 
was accused of releasing sarin on rebel forces in August of 2013.5 As a result of these attacks and 
to avoid backlash from the international community, Syria agreed to destroy their stockpiles and 
sign the CWC as of September 2013. These recent attacks serve as somber reminders to the 
international community that, despite the regulations and laws that have been in place for over 
twenty years, these chemical weapons still pose a real threat to humanity. 
Table 1 demonstrates the main classes and structures of the Schedule I CWA as 
determined by the CWC.1 In addition to these compounds, many of their precursors are also 
considered Schedule I CWA. In order for these compounds to be considered Schedule I, they 
must, among other considerations, have been specifically developed, produced, or stockpiled for 
use as chemical weapons. In addition, these compounds must have “little or no use for purposes 
not prohibited under this Convention” – in other words, they cannot be used (or have very few 
uses) for anything else except for chemical warfare.  
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Class of CWA Compound Name Structure 
Nerve Agents 
Sarin 
P O
O
F
 
Soman 
P O
O
F
 
Tabun 
P
O
ON
N  
VX P
O
O
S
N
Blister Agents 
Sulfur Mustard S
ClCl
 
Lewisite As
Cl
ClCl
 
Nitrogen 
Mustard N
R
ClCl
HN-1: R = CH2CH3
HN-2: R = CH3
HN-3: R = CH2CH2Cl
Neurotoxin Saxitoxin 
NNH
NH
N
OH
OH
NH2
NH
O
NH2
O
 
Protein Synthesis 
Inhibitor Ricin 
 
Table 1: Schedule I CWA as determined by the Chemical Weapons Convention. 
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Of these CWAs, some of the most lethal agents are the organophosphate (OP) nerve 
agents, of which sarin is a member. Organophosphate nerve agents are related to phosphorous-
containing pesticide compounds, and their primary mode of action is to inhibit 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the body. These two enzymes 
are primarily responsible for the breakdown of the neurotransmitter acetylcholine (ACh) in 
neuronal synapses. Acetylcholine serves a variety of functions in the nervous system, including 
its role in the peripheral nervous system activating neuromuscular junctions via interaction with a 
post-synaptic binding site. 
In normal biological functions, ACh is released by a pre-synaptic neuron and, when 
properly linked into the ACh receptor on the post-synaptic neuron, a signal for the contraction of 
muscles in the body is produced (Figure 1).6 Acetylcholinesterase and BuChE are responsible for 
the breakdown of ACh in the synapse so that it does not overstimulate the post-synaptic neuron. 
However, when nerve agents are present, these enzymes are blocked, due to nerve agent binding 
to the active serine (Ser) site on the enzyme. Consequently, ACh is consistently present in the 
synapse without means of breaking down; therefore, ACh overstimulates the post-synaptic 
neuron, causing continuous and uncontrollable muscular contractions.7 Eventually, an individual 
exposed to nerve agents without any treatment will die via asphyxiation and other physiological 
effects.  
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Figure 1: Mechanism of OP toxicity. 
 If caught early enough, nerve agent exposure can be treated with anticholinergic drugs or 
compounds such as pralidoxime (2-PAM) to reactivate the blocked AChE. Compounds such as 2-
PAM work by dephosphorylating the active Ser on AChE; however, there is a point at which 2-
PAM is no longer effective due to a process called “ageing” (Figure 2). Ageing occurs when the –
OR group (or the phosphoramide bond in the case of tabun8) is hydrolyzed, thus creating a 
stronger bond between the hydrolyzed nerve agent and the serine binding site. Once this process 
occurs, compounds such as 2-PAM cannot break the bond and other treatment methods (such as 
the administration of anticholinergic drugs) must be utilized.9  
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Figure 2: Mechanism of OP binding to active Ser on AChE, followed by ageing process.  
Sarin: R1 = CH(CH3)2; R2 = CH3; R3 = F  
Soman: R1 = CH(CH3)(t-butyl); R2 = CH3 R3 = F  
VX: R1 = CH2CH3; R2 = CH3; R3 = SCH2CH2N[CH(CH3)2]2  
Tabun: R1 = CH2CH3; R2 = N(CH3)2; R3 = CN 
 
Analytical methods for OP nerve agents are quite varied and depend on the matrix tested. 
In aqueous, atmospheric, or even soil samples, hydrolysis products of nerve agents are most 
stable and therefore most commonly found in these types of matrices. These hydrolysis products 
tend to be polar, non-volatile compounds and thus easiest analyzed via liquid-chromatography-
mass spectrometry (LC-MS)10 or even capillary electrophoresis (CE)11. However, with 
derivatization, gas chromatography-mass spectrometry (GC-MS) analysis is also possible,12,13 and 
is arguably the most common method of analysis.14 In biological matrices, metabolites of these 
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nerve agents may be extracted from plasma and detected directly;15 however, these techniques 
may suffer in terms of sensitivity, as there may not be as much free nerve agent or circulating 
metabolites as there are bound to AChE or BuChE. For this reason, biological detection of nerve 
agents most often occurs via a process called fluoride reactivation, in which the extracted plasma 
is inundated with a high concentration of fluoride ions, which can break the covalent 
phosphoserine P-O bond, producing a fluorinated compound that can be detected quantitatively 
via GC-MS.16-19 While this method can be highly sensitive, its major drawback is if the 
organophosphate has aged onto the serine residue, in which case it cannot be reactivated by this 
method. However, it is possible to analyze the nerve agent still attached to plasma BuChE via its 
isolation from plasma and subsequent digestion with enzymes such as chymotrypsin20, pepsin21, 
or other digestion enzymes.       
Vesicants, better known as blister agents, are a second class of CWA. Blister agents are 
chemicals that can cause tissue blistering and ocular and respiratory damage. Unlike the nerve 
agents discussed previously, the action of these bister agents appears to be much more non-
specific in terms of a target enzyme or organ; however, the observed “blistering” effect appears to 
be a result of a separation of the epidermis from the basement membrane in the skin.22 In addition 
to these blistering effects, vesicants such as HD and the family of nitrogen mustards (HN) form 
highly electrophilic intermediates (sulfonium ion with HD; aziridinium ion with HN) in aqueous 
solutions which can bind to DNA and other macromolecules, producing a multitude of different 
effects including apoptotic DNA fragmentation and protein cross-linking.23-27   
Of the Schedule I blister agents, HD is by far the most notorious. HD was first used by 
the Germans in WWI (1917), and was the main contributor of gas-related casualties during the 
war.7 Commonly referred to as “mustard gas” because of a potential odor imparted by synthetic 
impurities, HD is in fact not as gas at all, but an oily liquid that can be aerosolized for use as a 
chemical weapon. As a result of pure HD’s low water solubility, it can be highly persistent in the 
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environment, causing a problem not only for those immediately exposed, but for individuals who 
may pass by a contaminated area even days after.22 There are several different permutations of 
chemical mixtures that are classified as “sulfur mustards,” which can be seen in Table 2;22 the 
designation “HD” typically refers to vacuum distilled bis(2-chloroethyl)sulfide, as seen in Table 
1. 
Sulfur Mustard Type Symbol Description 
Distilled Mustard HD bis(2-chloroethyl)sulfide (approx. 97%) achieved via vacuum distillation 
Levenstein Mustard H, or Agent H 
mixture of HD (70%) and other sulfur impurities 
(30%) 
Agent HT mixture of HD (~ 60%) and bis(2-chloroethylthioethyl)ether (~ 40%) 
Sulfur Mustard-Lewisite 
Mixture HL ratios vary; developed for cold-weather use 
Sesqui Mustard Q 1,2-bis(2-chloroethylthio)ethane 
HQ mixture of HD and Q  
Half-mustard CEES 2-chloroethyl ethyl sulfide 
Table 2: Various compositional permutations of "Sulfur Mustard." 
A second type of Schedule I blister agent is Lewisite, an arsenic-containing vesicant. 
While Lewisite was developed in the hopes of creating an improved blister agent over HD, its 
rapid hydrolysis to 2-chlorovinylarsonous acid (CVAA, as seen in Figure 3) in aqueous 
environments renders it less effective than previously hoped. Despite this shortcoming, Lewisite 
has been stockpiled as a mixture with HD for weapon use.22 Of all the blister agents, Lewisite is 
the only one with an antidote – dimercaprol, better known as British anti Lewisite (BAL) – which 
shows a high affinity for CVAA both in free plasma and bound to proteins.28 
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As
Cl
ClCl
As
OH
OHCl
(1) (2)
(3) SH OH
SH  
Figure 3: Hydrolysis of Lewisite (1) to CVAA (2); structure of British anti Lewisite (BAL). (3) 
 The third class of blister agents, and the focus of this work, is a group of compounds 
collectively known as nitrogen mustards (HN). Three different HN compounds are currently 
listed as Schedule I CWA, and can be seen in Table 1. These compounds are structurally and 
chemically similar to HD; therefore, their properties as CWA are similar to that of HD. The 
formation of the positively charged aziridinium ions (Figure 4) is largely responsible for the 
toxicity of HN through DNA and protein binding.29  
N
R
ClCl N
+
R
Cl N
R
ClOH
N
R
ClProtein
N
R
ClDNA  
Figure 4: Formation of electrophilic aziridinium ions for nitrogen mustard compounds. The identity 
of the R-group defines the types of CWA (See Table 1 for structures). 
 
Unlike the OP nerve agents, the molecular mechanism for blister agent toxicity is still 
largely undetermined,30 although several hypotheses exist that attempt to explain their deleterious 
effects. The consensus of the literature on HN compounds is that DNA and protein binding via 
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the aziridinium ion is a primary component of toxicity. However, other potential mechanisms of 
toxicity of HN compounds have also been suggested, involving the formation of free radicals,23  
oxidative damage to the lungs,31,32 the formation of reactive oxygen and reactive nitrogen 
species,33  and activation of inflammatory pathways,34 specifically in skin.35  
As with the nerve agents, there are a variety of methods by which blister agents can be 
detected. When assessing environmental samples, the detection of the hydrolysis products of 
these compounds – CVAA for Lewisite, and the replacement of chlorine with hydroxyl groups in 
HD and the HN family – provides more sensitive detection of these compounds over the parent 
compounds.28,36-38 Most commonly, these polar compounds are detected via LC-MS or GC-MS 
following derivatization.39,40 The analysis of biological samples offers more variety in terms of 
detection. In general, HD, the HN compounds, and Lewisite have short plasma half-lives;41-43 
therefore, hydrolyzed free agents in either plasma or urine tend to be the target compounds of 
interest. In addition, β-lyase and glutathione (GSH) conjugates have also been reported with HD 
exposure.39 As glutathione conjugation is a major pathway for detoxification of electrophiles in 
the body,44 it would also be expected that glutathione conjugates would be observed for HN and 
CVAA.45,46 In theory, protein adducts may also be utilized for blister agent detection, once 
adduction sites have been properly characterized. Detection methods for such adducts involve 
isolation of a relevant macromolecule, digestion via one or more proteases, and peptide analysis 
via LC-MS.47 Protein adduction will be covered in greater depth in Section 2.4, and protein 
adduct analysis will be covered in Section 2.5. 
2.2. Biomarkers of Exposure 
A biomarker of exposure is defined as a biochemical alteration of some kind found in the 
body that can be used to determine whether an individual has been “exposed” to a xenobiotic of 
interest. The exposure may be intentional or unintentional – for example, an individual may take 
a pain reliever for a headache, representing an intentional exposure, or a worker may be exposed 
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to toxic vapors as a result of industrial byproducts, which would be a result of an unintentional 
exposure. Regardless of intent, these exposures are represented through the presence of certain 
markers in the body, which, once identified, can be detected through analytical and bioanalytical 
methods. Exposure biomarkers are highly varied both in terms of type and specificity,48 and can 
include something as simple as detection of the parent compound to a more complex marker such 
as the covalent adduction of the compound to a macromolecule. These biomarkers are important, 
as ambient or environmental levels of a compound do not necessarily correlate to an individual’s 
exposure. In contrast, biomarkers have the advantage of providing a direct connection between 
the compound and the individual.49  
The simplest form of a biomarker is monitoring the xenobiotic of interest or its 
metabolites directly in a biological specimen. These types of biomarkers are most commonly 
utilized in forensic toxicology and the medical community in terms of drug monitoring in illicit or 
clinical cases, respectively. In order to use these types of biomarkers for detection, it is important 
to know what permutation of the compound of interest is present in the tested biological fluid. For 
example, a parent compound may be seen in an individual’s serum; however, if urine is the 
matrix being analyzed, it is more likely to contain metabolites of the compound. These 
considerations and an understanding of the biotransformation of these compounds in the body are 
important for accurate determination of exposure.50 
A second type of biomarker of exposure includes adducts formed on macromolecules 
such as DNA or protein, formed when an electrophilic xenobiotic of interest (or a reactive 
intermediate) forms a covalent bond with a nucleophilic residue on the macromolecule. Table 3 
lists the most commonly adducted nucleophilic sites of  adduction for DNA and protein.49   
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Table 3: Most common DNA and protein residues for electrophilic adduction. Arrows point to the 
potential reactive sites on DNA residues. 
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 The inherent nucleophilicity of these bases or amino acids plays an important role in 
whether a DNA or protein adduct will form; however, adduction cannot be predicted with this 
property alone. Other important factors that influence xenobiotic adduction include the relative 
electron density of both the nucleophile and the electrophile – in other words, the relative 
“hardness” or “softness” of these reactive species.51 The more compatible the nucleophile and 
electrophile are along this scale, the more likely a stable covalent bond will form. Other localized 
factors such as the steric accessibility of the nucleophilic site and the electronic environment 
surrounding the site may also have an effect.49 Further detail regarding the formation of protein 
adducts is discussed in Section 2.3 
 In order for a biomarker of exposure to be useful, several key characteristics need to be 
met.52 First (and most importantly in terms of forensic applications), the biomarker should be 
specific to the xenobiotic in question. While the use of metabolites as biomarkers of exposure is 
arguably a simpler method of detection, metabolites do not always meet this first characteristic. 
For example, nitrogen mustards rapidly hydrolyze to ethanolamines in aqueous solutions (such as 
blood), and are thus the major metabolites seen both in plasma and excreted in urine. However, 
these metabolites are not specific to HN exposure, as ethanolamines themselves may be used for 
industrial or personal applications.53 For this reason, a different biomarker of exposure should be 
selected for CWA HN exposure determination. This uniqueness criterion may be satisfied by 
utilizing protein or DNA adducts as exposure biomarkers, because such adducts would not form 
in the absence of the xenobiotic. In addition, not all metabolites are reactive and therefore may 
not adduct to nucleophilic sites; therefore, this may add a level of specificity for the compound of 
interest if it has a reactive metabolite capable of macromolecular adduction. However, caution 
must be utilized, as drugs with similar structures may form the same reactive metabolites. 
The second key characteristic for an ideal biomarker of exposure is a relatively long 
lifetime in the body. This is important in cases where the time between exposure and sample 
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collection or analysis is long. While some xenobiotics may have long-circulating metabolites, this 
is problematic when using metabolites as biomarkers of exposure for HN. As these compounds 
hydrolyze so quickly, they are subsequently rapidly excreted from the body as a result of an 
increase in polarity of the compound.  
The final characteristic for an ideal biomarker is that it should demonstrate stability in 
biological matrices. Related to the second listed characteristic, stability allows for a more reliable 
marker over time and when analyzing samples from multiple individuals. This point is important 
when considering DNA adducts as potential biomarkers of exposure. Due to the critical 
importance of DNA in living systems, several highly efficient repair mechanisms exist to ensure 
that the integrity of DNA remains intact. Xenobiotic adduction of DNA may therefore trigger 
these repair mechanisms, thus making these biomarkers potentially less stable than protein 
adducts, where repair mechanisms are minimal or nonexistent.54  
Based on the abovementioned criteria, protein adducts can therefore provide a specific 
biomarker of exposure for a xenobiotic of interest. Ideally, adducts to a target protein for the 
particular xenobiotic would produce the most sensitive biomarker; however, in the case that the 
target protein is unknown or inaccessible, other proteins may be utilized. Two of the most 
common proteins employed for biomonitoring are hemoglobin (Hb) and human serum albumin 
(HSA). These two proteins are well suited as biomonitors because of several favorable 
characteristics. First, blood is relatively easily obtained from individuals. Second, these two 
proteins are highly abundant in blood – one mL of blood contains approximately 150 mg of Hb 
and 30 mg of HSA. In contrast, in this same mL of blood, only a small amount of DNA is 
present.54 Finally, both Hb and HSA have known kinetic rates of turnover in the body – Hb 
circulates in the bloodstream for approximately four months, and HSA has a half-life of 
approximately 20 days in humans.55 Because of their long circulation times, adducts to these 
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proteins have the potential to be detected much longer after exposure than parent compounds or 
circulating metabolites. 
2.3. Protein Adduction Mechanism 
The formation of protein adducts depends on several factors; however, it ultimately 
comes down to the relative nucleophilicity of the amino acid site on the protein and the 
electrophilic nature of the xenobiotic of interest. Most xenobiotics will undergo some kind of 
biotransformation (whether passive or enzymatic) to a more reactive electrophilic species.56 
These electrophilic species may then bind to nucleophilic centers on proteins; however, the 
reactivity of these sites varies and is affected by several different factors.   
The first factor to consider is the local electronic environment of an amino acid in a 
protein. Not all amino acids are nucleophilic at physiological pH – depending on the pKa of the 
amino acid, some amino acids may be more likely to demonstrate electrophilic qualities (i.e., a 
positive charge) and therefore not provide a binding site for electrophilic xenobiotics. It is also of 
importance to note that, while amino acids may have a "base" pKa value, it is possible that, 
depending on both long-range and local electrostatic influences in the protein structure, a lower or 
higher local pKa may occur for a particular residue.57 For example, while cysteine (Cys) is 
considered the softest biological nucleophile and thus one of the most reactive sites for protein 
adduction, its base pKa value is ~8.3, meaning that at physiological pH (7.4), the majority of Cys 
residues would be unionized (i.e., in the thiol form) and therefore not be in the more favorable 
thiolate form (S-) for adduction. However, reactive Cys groups in biological proteins often exist 
in an arrangement where neighboring basic or acidic amino acids facilitate the deprotonation of 
the thiol to produce the thiolate, which is then susceptible to electrophilic modification.58 Other 
amino acids capable of such pKa modification include aspartic acid (Asp), glutamic acid (Glu), 
histidine (His),lysine (Lys), tyrosine (Tyr), and the protein terminal groups (both the C-terminus 
and the N-terminus).57 Similar variability of local pKa values have been seen with both Lys59 and 
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His60 residues on a variety of biological proteins. Therefore, despite the base Lys pKa of ~10.4, 
these local electronic factors may lower the pKa of a residue to the point at which is it uncharged 
at pH 7.4 and therefore available for adduction by electrophilic species. As the base pKa of His is 
~ 6, these electronic effects are not as significant, as the majority of His side chains are unionized 
at pH 7.4; however, it may still play a role in electrophilic adduction. 
 Second, even if an amino acid is sufficiently nucleophilic, steric factors will also play a 
role in whether protein adducts will occur.61 This applies both to the nucleophilic site and the 
attacking electrophile. Some electrophilic species may be too bulky to adduct, or a nucleophilic 
site may be hindered by surrounding amino acids that do not allow for adduction. Hypothesized 
adduction sites may therefore exhibit enhanced reactivity if the site is not hindered by other 
amino acids or other components of a protein's structure.  
While inherent nucleophilicity and electrophilicity are important for the formation of 
protein adducts, it is also important to consider a second characteristic of the reacting species. A 
compound's "hardness" or "softness" is a description of the relative electron density surrounding a 
reactive site and its overall polarizability. Compounds are classified as generally "soft" when they 
have a large electron density (as seen with compounds with an extended  electron network) and 
are highly polarizable. Compounds are classified as generally "hard" when they exhibit the 
opposite characteristics - typically, these compounds will have a relatively small electron density 
(a centralized location of charge) that is less polarizable. These characteristics are directly related 
to the outermost orbital energies (the Highest Occupied Molecular Orbital, or HOMO and the 
Lowest Unoccupied Molecular Orbital, or LUMO) for the respective compounds.62 The Hard and 
Soft Acid-Base (HSAB) theory states that compounds classified as soft are more likely to interact 
with other soft compounds, and vice versa.51 Therefore, predictions as to whether an electrophile 
and nucleophile will interact favorably can be done using quantum mechanical calculations based 
on the HOMO and LUMO energies for the nucleophilic and electrophilic species.  Equation 1 
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demonstrates the calculation for “hardness” (η): 
ߟ ൌ 	 ሺܧ௅௎ெை െ	ܧுைெைሻ2  
Equation 1: Calculation of hardness.62 
The higher the calculated hardness value, the more the species in question can be classified as 
"hard." Conversely, the lower the calculated hardness value, the more the compound is classified 
as “soft.” It is important to note that there is not a "cutoff" value at which a compound is labeled 
as "soft" or "hard" - values may be used as a comparative tool between various electrophiles or 
nucleophiles, but only with experimental data can binding be confirmed.62  Hardness can be 
calculated for both the electrophilic and nucleophilic species of interest. The closer these values 
are to each other, the more similar those two species are in terms of hardness (and, thus, more 
likely to react). 
 The calculated value for hardness may be combined with a second calculated value 
known as chemical potential (μ), which describes a molecule’s ability to transfer electron density 
to a different molecule. This characteristic can therefore be used to describe a compounds 
inherent nucleophilicity – the larger the calculated chemical potential, the better a compound is at 
transferring electron density, and therefore, the stronger its nucleophilic qualities. Chemical 
potential is also calculated using the HOMO and LUMO energies for a compound of interest 
(Equation 2): 
ߤ ൌ 	 ሺܧ௅௎ெை ൅	ܧுைெைሻ2  
Equation 2: Calculation for chemical potential.62 
 As previously stated, the two most important factors for predicting whether two species 
will form covalent bonds are the nucleophilicity/electrophilicity of the reacting species (as 
calculated by Equation 2 above), and their relative hardness or softness (as calculated by 
Equation 1 above). As such, a third equation may be utilized that combines the calculated 
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hardness and chemical potential for a nucleophile and electrophile of interest to produce a 
“Reactivity Index” (ω-),63  as seen in Equation 3: 
߱ି ൌ 	ߟ஺ሺߤ஺ െ	ߤ஻ሻ
ଶ
2ሺߟ஺ ൅	ߟ஻ሻଶ  
Equation 3: Calculation for reactivity index, where A = nucleophile and B = electrophile. 
The Reactivity Index can be utilized to compare the predicted reactivity of several electrophiles to 
a nucleophile of interest, and has demonstrated good agreement with experimental determinations 
of nucleophile-electrophile interactions.62   
 Values for the HOMO and LUMO energies for selected electrophilic and nucleophilic 
species may be obtained through the use of quantum mechanical software that will calculate these 
energies based on the lowest energy conformation of a molecular structure. A variety of 
theoretical models exist for the modeling of a compound’s molecular orbitals; however, one of 
the most commonly used models is density functional theory (DFT), specifically the B3LYP 
model, which provides consistent and efficient results for whole-molecule modeling of most 
compounds.64  
A final consideration for protein adduction involves the function of the amino acid 
residue to be adducted, and the function of the adducted protein in general. For example, the 
functions of proteins such as metallothionein is to act as scavenger proteins and trap reactive 
species (such as free radicals and metals) within the body.65 Therefore, identification of 
metallothionein-based protein adducts may be quite useful, and such adducts might be prevalent 
after xenobiotic exposure due to its cysteine-rich structure; however, their short circulation time 
in the body may limit their usefulness as long-term biomarkers.66 In contrast, a protein such as 
hemoglobin has a specific function (oxygen transport) that does not include detoxification.67 An 
adduct that interferes with this function is highly unfavorable, and while some modifications may 
be repaired, those that cannot would most likely result in the adducted Hb being destroyed.68 
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These adducts would therefore be less stable (and as a consequence, not a reliable exposure 
biomarker) than adducts which do not alter the function of the protein. However, should 
xenobiotic adduction occur on Hb and not alter its oxygen transport function, it has the potential 
to remain on the protein during its lifetime in the blood. 
2.4. Protein Adduction by Chemical Warfare Agents 
Previous research regarding protein adduction of CWA has generally been determined 
based on the known active sites of these agents. In the case of the OP nerve agents, adducts to 
AChE8,69,70 and BuChE20,21,71 are commonly used. As these proteins are considered the main 
targets of nerve agents, such adducts make for sensitive exposure biomarkers and have been 
detected in a number of instances with both in vitro and in vivo exposure. However, there have 
been other protein adduct biomarkers identified for these agents. Williams et. al72 and others73-75 
identified adduction of sarin, soman, tabun, and VX to a Tyr residue (Tyr-411) on HSA. These 
adducts were identified as stable for up to a week after subcutaneous exposure to guinea pigs and 
did not appear to be affected by oxime (2-PAM) therapy. This adduction site is not unique to the 
CWA organophosphates - adduction to Tyr-411 has also been identified with chlorpyrifos, a 
common OP pesticide used in agriculture.76  The identification of OP protein adducts has been 
done in a variety of ways, most commonly of which involves the regeneration of the active Ser 
and subsequent release of the nerve agent(s) for analysis via GC-MS.16,18,19,77,78 More classic 
proteomic techniques involve the use of a digestive enzyme such as trypsin,72 chymotrypsin,20 or 
pronase74 for isolation of a peptide containing the adducted residue and subsequent analysis via 
LC-MS and liquid chromatography tandem mass spectrometry (LC-MS-MS).  
 Adducts to blister agents, most research of which has focused on HD, are diverse in terms 
of protein targets, as the critical protein target(s) of these agents have yet to be identified. HD 
adducts have been characterized  on the Cys-34 residue of HSA,79-81 the N-terminal Val of Hb,82-
85 keratin,86,87 keratinocytes,88 glutathione,89 metallothionein,90 and cell membrane proteins such 
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as actin.27 Additional HD protein adduction sites on Hb included His, Glu, and Asp. It was 
determined that His adduction was most prominent; however, adducts could not be sensitively 
analyzed given the methodology used (GC-MS) in these earlier studies.83,84 The identification of 
Cys-34 adduction has been widely done with pronase digestion and characterization of the 
adducted tri-peptide cysteine-proline-phenylalanine (Cys-Pro-Phe) via LC-MS-MS analysis. 
Despite pronase's general low specificity in terms of protein digestion, identification of the 
reaction site was made possible via a comparison to a synthesized tri-peptide standard and use of 
radiolabeled HD.80,91 Identification of N-terminal adduction of Hb was performed via a modified 
Edman Degradation process, in which the classical Edman reagent (phenyl isothiocyanate) was 
replaced with a pentafluoro derivative (pentafluorophenyl isothiocyanate), allowing for the 
selective removal of the modified valine (Val) residue.92  
Protein adduct research for the nitrogen mustard family has been less extensive than that 
for the OP nerve agents and HD; however, it has followed in the same vein as its blister agent 
relative. Protein adducts to nitrogen mustard CWA (mostly HN-2) have been identified on Cys-34 
of HSA,93 N-terminal Val of Hb,94 glutathione,41 and metallothionein.95   However, most research 
regarding HN has been focused on detection of DNA adduction and cross-links,24,25,96 which has 
led to the development of multiple drugs containing the nitrogen mustard moiety (further 
discussed in sections 2.6 and 2.7 regarding therapeutic HN compounds and in vitro metabolism, 
respectively). Available methods for HN adduction determination are similar to those seen with 
HD. 
 Considering the significant physicochemical similarities between HD and the nitrogen 
mustard agents, it is expected that the HN CWA would adduct to similar sites as seen with HD. 
However, the nitrogen center (as compared to the sulfur center) exhibits some "harder" 
electrophilic qualities that may allow for nitrogen mustards to bind to a wider variety of 
nucleophilic centers, most notable Lys and His, which are moderately hard nucleophiles and 
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therefore may align well with HN reactivity.97These could represent important and largely 
unexplored alternative adduction sites.  Consequently, further research is needed to identify 
additional, potentially more specific and reliable exposure biomarkers of HN CWA based on 
protein adducts. 
2.5. Bottom-Up Proteomics 
In general, mass spectrometry (MS) based proteomic analysis can be split into two 
different classes of analysis which are dependent on the approach an analyst uses to work with the 
protein in question. The first method, known as "top-down" proteomics, starts with a whole 
protein introduced into a mass spectrometer, which is then fragmented in the collision cell into 
peptides. The masses of these peptides are then matched using bioinformatics tools to identify the 
protein. The second method, known as "bottom-up" proteomics, utilizes enzymatic cleavage of a 
full protein prior to its introduction into the mass spectrometer. Tandem mass spectrometry (MS-
MS) is utilized to fragment enzymatically cleaved peptides, and the resultant ions analyzed (again 
using bioinformatics approaches) to elucidate an amino acid sequence for each peptide (Figure 5). 
This method is most typically used for the identification of post-translational modifications, 
particularly when the modification creates a predictable mass shift that can be observed via MS or 
MS-MS. For this reason, bottom-up proteomics is very useful for the determination of xenobiotic 
adduction sites on proteins, as they also create a mass difference between the native peptide mass 
and the adducted peptide mass. If the mass increase is well characterized, adduction sites can be 
identified with high confidence.  
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Figure 5: Bottom-up versus top-down proteomics.98 Bottom-up analysis involves enzymatic digestion 
of the protein prior to MS analysis, whereas top-down analysis utilizes the fragmentation capabilities 
of the MS for identification. 
 
When peptides are introduced into an MS collision cell, they tend to fragment in a very 
specific manner, which is quite useful when analyzing an MS-MS spectrum to elicit amino acid 
composition and sequence. Figure 699  demonstrates the typical fragments observed with peptide 
MS-MS, including conventional descriptors for each fragment. 
 
Figure 6: Description of peptide MS-MS fragments. Typical fragmentation results in formation of b 
and y ions; however, a and x fragments may also be encountered based on collision energy 
parameters.99 
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Bottom-up proteomics is also quite useful when the protein in question is well 
characterized (i.e., containing a known amino acid sequence) and when an enzyme with well-
characterized cleavage sites is utilized for digestion. Typically, trypsin is used, a serine protease 
that cleaves at the carboxy-terminus of Lys and arginine (Arg) residues, except when followed by 
a Pro. Trypsin has a high level of specificity, making it an excellent choice for a predictable 
digestion enzyme.100 However, should a protein of interest contain few (or too many) Lys or Arg 
residues, trypsin would not be well suited as it would form large (or very small) fragments that 
are more difficult to analyze. Therefore, other enzymes are also available for protein digestion, 
and can be utilized based on experimental requirements and conditions.  
 A variety of software packages may be used to assist in the identification of post-
translational modifications or xenobiotic adducts. These programs utilize the obtained peptide 
mass for both MS and MS-MS data and match it to potential iterations of a known peptide (i.e., 
found via a database or in-house specification of protein and peptide sequences) or a peptide with 
a modification of some kind. Because of this matching process, it is important to collect highly 
accurate MS and MS-MS data so as to provide a high confidence match to identify individual 
peptides and, thus, the starting protein. Therefore, data collection should be done on a high-mass 
accuracy instrument for best results. The use of MS-MS based approaches for proteomic data 
collection and analysis has offered great improvements over previous proteomic approaches such 
as gel electrophoresis. As mentioned above, it is important to consider software specification 
when determining which mass analyzer to utilize. However, it is also important to consider the 
advantages and disadvantages of each MS system, and use these qualities wisely to obtain the 
desired results.  
The first consideration is the type of ionization required for the analysis of choice. As the 
majority of bottom-up proteomics involves multiple peptides formed after enzymatic digestion, it 
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is highly desirable to incorporate some type of chromatographic separation for improved analysis. 
As peptides are non-volatile analytes, liquid chromatography (LC) is the separation technique of 
choice and, as such, an ionization technique such as electrospray ionization (ESI) is most 
commonly used, as it is easily coupled to LC.101 Electrospray ionization is an atmospheric 
pressure ionization technique in which a liquid (specifically, the LC effluent) is introduced into a 
charged capillary, which is held at a high potential (typically positive) as compared to a ground. 
This charge differential creates the formation of a Taylor cone at the tip of the capillary as the 
effluent travels out the capillary. Charged droplets are released from the Taylor cone and 
desolvated in the high temperature source, leaving behind charged peptide ions that are 
subsequently introduced into a mass analyzer (Figure 7).102  While it is also commonplace to use 
other ionization sources for proteomic analysis (such as Matrix-Assisted Laser Desorption 
Ionization, or MALDI), the ease with which ESI ionization can be coupled to LC allows for 
analysis of chromatographic effluent that could only be achieved with MALDI via fractionation 
and analysis of each fraction individually. In addition, the common production of multiply-
charged species in ESI (MALDI typically produces singly charged ions) may allow for the 
analysis of larger peptides even when a mass analyzer has a relatively narrow m/z range.101 
26 
 
Figure 7: Positive model electrospray ionization (ESI).102 The analyte solution is given a charge 
through the capillary, creating highly charged droplets that are desolvated before entering the mass 
spectrometer. 
 
 The second important item to consider is the type of mass analyzer and its suitability for a 
specific proteomic application. While there are several mass analyzers to consider, this review 
will focus on the two analyzers utilized during the present research – triple quadrupole (QQQ) 
and quadrupole-time-of-flight (Q-TOF) analyzers.  
 The QQQ analyzer is a highly versatile mass analyzer that is composed of three 
quadrupoles in tandem, with the center quadrupole acting as a collision cell. This arrangement of 
analyzers in either a fixed or scanning mode can allow for a variety of MS and MS-MS 
experiments, including MS Scan, Single-Ion Monitoring (SIM), Product Ion Scan, Neutral Loss 
Scan, and Multiple Reaction Monitoring (MRM) (Figure 8). Of specific interest to proteomic 
research is the MS-MS capabilities of the instrument (Product Ion Scan, Neutral Loss Scan, and 
MRM). These types of MS-MS experiments can allow for the analysis of peptides that contain 
similar sequences or modifications while minimizing unwanted data. In addition, MRM can allow 
for a highly selective and sensitive method for detecting a known peptide of interest.103  However, 
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QQQ analyzers do not produce high mass accuracy data, which are essential when attempting to 
identify unknown peptides or modifications. Triple quadrupole analysis is therefore best suited 
when the peptides and modifications are well known so as to take advantage of its high selectivity 
and sensitivity. 
 
Figure 8: Various modes for QQQ analysis.103 Multiple Reaction Monitoring is a highly selective and 
sensitive method that may be used in proteomic analysis once post-translational modifications have 
been successfully identified. 
 
 The Q-TOF mass analyzer is capable of producing high mass accuracy data due to the 
time-of-flight (TOF) analyzer. Ions are “pushed” into a flight tube under vacuum, in which all 
ions are given the same kinetic energy entering the tube. Ions will travel through the tube and 
reach the detector at a speed that is inversely proportional to the mass-to-charge (m/z) ratio of the 
ion (Figure 9).104 The incorporation of the quadrupole at the front end and a collision cell between 
the two analyzers allows for MS-MS analysis that produces high mass accuracy product ions, 
which is necessary for accurate database matching of unknown peptides. In addition, the accurate 
mass data is also helpful when attempting to identify protein modifications, both known and 
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unknown. However, Q-TOF instruments are not capable of the same sensitivity that can be 
achieved using MRM mode on a QQQ instrument.103 Nevertheless, these two instruments may be 
used to complement each other – Q-TOF analysis can be done to identify a peptide of interest, 
and QQQ analysis may be done to increase the sensitivity of its detection once the peptide has 
been identified and characterized. 
 
Figure 9: Schematic of quadrupole-time-of-flight (Q-TOF) mass analyzer.104 The Q-TOF is 
particularly useful in proteomics when a modification has not yet been positively identified due to its 
ability to produce high mass accuracy data. 
2.6. Nitrogen Mustard Therapeutic Agents 
Due to the success of HD as a chemical weapon, research began after WWI to develop an 
analogue of HD as a more efficient CWA. As nitrogen mustards were being investigated, it was 
observed that administration of these compounds could treat a variety of cancers, most notably 
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leukemia.2 As such, therapeutic agents containing these nitrogen mustard moieties were 
developed as cancer treatments.  
As mentioned previously, known adduction sites for electrophilic species include sites on 
DNA bases, most notably the N-7 position of guanine. When adducted to DNA, HN compounds 
are able to form a variety of mono- and bi-alkylated products, including DNA intra- and inter-
strand crosslinks, and DNA-protein crosslinks.105 When this occurs in rapidly dividing cells (as is 
the case with cancer), this cross-linking can induce apoptosis, thus treating the disease.106 
However, this cross-linking is also associated with cytotoxicity in healthy cells;107 as such, 
development of drugs with a higher therapeutic index was necessary for a more targeted approach 
to the cancer cells over healthy cells. For example, pro-drugs such as cyclophosphamide and 
ifosphamide were designed to contain a phosphate bond that could be cleaved in cells with high 
phosphoramidase activity (as in certain gastric cancers), producing an active phosphoramide 
mustard that could either react itself, or be further metabolized to nornitrogen mustard.108-110 More 
recently, dinitrobenzamide mustards have been developed that require activation via 
nitroreduction, produced by tumor cells.111-113 Other drugs, such as chlorambucil and melphalan, 
can adduct DNA directly without the need of metabolic activation.46,106 Figure 10 shows the 
structure of some of the more common nitrogen mustard based therapeutic compounds. 
The most common HN-containing therapeutic drugs currently utilized are cyclophosphamide 
(CP), chlorambucil (CB), and melphalan (MP). These drugs are capable of treating a wide variety 
of cancers, including leukemia (CP, CB), lymphoma (CP, CB), ovarian cancer (CP, CB, MP), 
breast cancer (CP, CB, MP), myeloma (MP), lung cancer (CP), and prostate cancer (CP).107 
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Figure 10: Structures of common therapeutic drugs containing the nitrogen mustard moiety. 
 Nitrogen mustard therapeutic compounds have demonstrated their ability to form DNA 
adducts and DNA cross-links at a variety of nucleophilic sites on DNA.24,46,114 In addition to 
binding to DNA, these compounds may also bind to the DNA repair protein O6-alkyguanine 
DNA alkyltransferase (AGT) and form DNA-protein cross-links, hindering AGT function and 
thus representing an alternative mechanism for these compounds.115 Resistance to these drugs is 
typically correlated with increased GSH and glutathione-S-transferase (GST) levels.107 CP, CB, 
and MP have all demonstrated the ability to form covalent bonds with GSH,116-119 which can act 
as a detoxification mechanism for these drugs.44  
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2.7. In Vitro Metabolic Assays 
In vitro metabolic assays are commonly used in drug discovery research as a way to 
assess the potential efficacy or toxicity of a new drug. The drug discovery process is both time-
consuming and quite costly, and these metabolic assays can assist in determining whether 
potential lead drugs are worth continuing to animal or clinical trials. Of largest concern is the 
metabolism of new drugs that may form reactive metabolites with deleterious effects. These in 
vitro assays can provide researchers insight into the potential formation of toxic metabolites.120 
The purpose of metabolism in the body is to transform drugs and other xenobiotics into 
more water-soluble compounds to facilitate their excretion from the body. Phase I metabolism 
typically involves oxidation, reduction, or hydrolysis reactions on the parent drug. During this 
process, reactive metabolites may form which, instead of being passively excreted, will interact 
with proteins or DNA and cause adverse reactions. The focus of most Phase I metabolism 
research has centered around the cytochrome P450 (CYP450) isoforms, as they account for 
approximately half of the metabolic enzymes responsible for drug metabolism.121 However, other 
enzymes, such as monoamine oxidases (MAO) and flavin-containing monooxygenases (FMO), 
are also quite common in Phase I metabolism. Phase II metabolism, or conjugation reactions, 
typically involve the addition of a large polar molecule (such as glucuronic acid) to a metabolite 
(or parent compound) to enhance excretion of compounds from the body. While many drugs 
typically undergo Phase I metabolism before Phase II metabolism, some drugs are primarily 
cleared from the body via conjugation.122 Figure 11 depicts the variety of mechanisms by which 
drugs can interact within the body. 
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Figure 11: Fate of drugs and xenobiotics in the body.120 Compounds may undergo various different 
metabolic activation processes, which have the potential to form reactive intermediates able to bind 
to proteins and/or DNA. 
 
One of the most commonly used in vitro metabolic assays for metabolite discovery 
involves the use of liver homogenate fractions as a medium for metabolism, the most common of 
which are the cytosolic fraction, the S9 fraction, and the microsome fraction. These fractions are 
obtained via the low speed centrifugation of a liver homogenate to obtain the S9 fraction 
(supernatant), which can be further centrifuged at high speed to obtain the cytosolic (supernatant) 
and the microsomal fraction (pellet). The microsomal fraction is one of the most popular in vitro 
models, and can provide a good prediction of hepatic CYP450 metabolism. Additionally, the S9 
fraction is quite useful due to its ability to produce both Phase I and Phase II metabolites.123 The 
ability of these liver homogenate fractions to mimic metabolic functions that typically occur in 
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living tissue involves the use of multiple cofactors that are normally present within tissues. The 
inclusion or exclusion of certain cofactors can allow for the manipulation of these fractions to 
perform Phase I or Phase II metabolism, or for experimental controls. 
Additional metabolic information may be elucidated by these metabolic systems with the 
use of nucleophilic agents such as glutathione to “trap” reactive metabolites that may not last long 
enough in the system to be otherwise detected. Other trapping agents, including short model 
peptides, may also be utilized to capture a wider variety of electrophilic species that may 
demonstrate a preference towards a nucleophile other than Cys.124 
 
2.8. Research Objectives 
This research was performed to test three main hypotheses: 
Hypothesis I: Nitrogen mustard chemical warfare agents are capable of forming stable adducts 
with lysine and histidine residues on model peptides and whole proteins. 
Hypothesis II: Identified adducts are specific to the chemical warfare agents and can be 
distinguished from potential adducts formed by the most common nitrogen mustard-containing 
therapeutic drugs. 
Hypothesis III: Identified adducts are stable over an extended period of time and thus are 
potential biomarkers for nitrogen mustard chemical warfare exposure. 
 
The goal of this project is to identify novel, specific, and stable protein adduct biomarkers 
of exposure to the chemical warfare agents HN-2 and HN-3. This was accomplished by 
completing the four tasks detailed below.  
Task 1: Determine the adduction potential of HN-2 and HN-3 to model peptides containing the 
reactive nucleophiles Cys, Lys, and His. Specifically: 
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 Determination of the relative kinetics of adduction of HN-2 and HN-3 to the model 
peptides over an eight h exposure period. 
 Determination of an optimal incubation time for HN-2 and HN-3 adduction for later 
experiments. 
 Determination of the stability of identified adducts over a three-week incubation period at 
physiological conditions (pH 7.4, 37ºC). 
 Assessment of the necessary concentration or molar excess of HN-2 or HN-3 required for 
observable adduction via liquid chromatography triple quadrupole mass spectrometry 
(LC-QQQ-MS) analysis. 
Task 2: Identify sites of adducted Lys and His residues on purified Hb and HSA after in vitro 
exposure to HN-2 and HN-3. Specifically: 
 Determination of a reproducible digestion protocol for Hb and HSA for peptide analysis 
via liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q-TOF-
MS) and liquid chromatography quadrupole time-of-flight tandem mass spectrometry 
(LC-Q-TOF-MS-MS). 
 Identification and characterization of Lys and His adducts that occur reproducibly with 
sufficient MS-MS support. 
 Determination of the stability of identified protein adducts over a three-week incubation 
period at physiological conditions.   
Task 3: Perform in vitro human whole blood incubations with HN-2 and HN-3 and determine 
whether adducts identified in Task 2 are present after protein isolation, purification, and trypsin 
digestion. Specifically: 
 Optimization of protein precipitation conditions for Hb and HSA isolation from human 
whole blood. 
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 Identification of novel Lys and His adducts on Hb and HSA (identified in Task 2) via 
MS-MS support and retention time matching. 
Task 4: Use in vitro metabolic systems to assess biotransformation and adduction of three of the 
most common therapeutic nitrogen mustard therapeutic drugs. Specifically: 
 Use model peptides containing Cys, Lys, and His as trapping agents for reactive 
metabolites formed in the in vitro system for each drug. 
 Determine whether, after metabolism, the therapeutic drugs will form the same identified 
adducts as HN-2 and HN-3. 
 
A fifth task was also completed using quantum chemical calculations to provide additional 
support for the findings from Tasks 1-3, in addition to providing avenues for future research. 
Task 5: Use molecular modeling software and quantum mechanical calculations to determine 
hardness, chemical potential, and reactivity index for relevant nucleophiles and electrophiles from 
this work. Specifically: 
 Compare hardness and chemical potential values of relevant electrophilic species for HN-
2 and HN-3 to those of a known reactive electrophile. 
 Compare hardness and chemical potential values of relevant amino acid species for 
prediction of reactivity to HN-2 and HN-3 based on experimental data. 
 Compare Reactivity Index values for relevant amino acids for specific electrophilic 
species for prediction of reactivity to HN-2 and HN-3 based on experimental data. 
 
Combined together, these tasks will 1) elucidate novel protein adducts and potential 
biomarkers of exposure for HN-2 and HN-3 that are specific to the analytes of interest and stable 
over time, 2) support these findings with quantum mechanical calculations, and 3) provide 
additional avenues of research for future work. 
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3. METHODOLOGY 
3.1. Instrumentation 
 Sample analysis by LC-QQQ-MS was performed on an Agilent 6460 triple 
quadrupole mass spectrometer, while samples analyzed via LC-Q-TOF-MS were performed on an 
Agilent 6530 quadrupole time of flight mass spectrometer. Both systems were coupled to an 
Agilent 1290 Infinity ultra-high performance liquid chromatography system utilizing Agilent Jet 
Stream ESI technology. Chromatographic separation was performed on an Agilent ZORBAX 
Rapid Resolution HD Eclipse C18 column (100 mm x 2.1 mm, 1.8 μm particle size), with a 
column temperature of 40°C. Solvents utilized for separation consisted of an aqueous phase 
consisting of 0.1% trifluoroacetic acid (TFA) in HPLC water and an organic phase consisting of 
95:5:0.1% acetonitrile:HPLC water:TFA. Method specifics for each task may be found in 
Appendix 6. Data acquisition for both systems was performed using Agilent MassHunter 
Acquisition software version 6.0 (QQQ) and version 5.0 (Q-TOF). Data analysis was performed 
using Agilent MassHunter Qualitative Analysis software, with supplementation by Agilent 
BioConfirm software (version 5.0) for full protein analysis (as seen in Appendix 5). 
 
3.2.  Model Peptide Adduct Screening 
 The identification of HN-2 and HN-3 adducts to the model peptides AcPAACAA, 
AcPAAKAA, and AcPAAHAA (custom synthesized by Biomatik, Inc.) were performed using 
LC-QQQ-MS. All adduction incubations were performed at 37°C in 10 mM sodium phosphate 
buffer (SPB), pH 7.4, so as to mimic human physiological conditions. Initial adduct identification 
was done by incubating 0.02 mg/mL of each peptide with excess HN-2 or HN-3 for 24 h and 
analyzed via full scan MS. Confirmation of identified adducts was done using product ion MS-
MS of the precursor ions identified via the full scan MS method. In addition, each model peptide 
was incubated with the HN-2 and HN-3 precursors N-methyldiethanolamine and triethanolamine, 
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respectively, to determine whether adduction would occur. For these experiments, 0.02 mg/mL of 
each peptide was incubated with excess N-methyldiethanolamine or triethanolamine at 37°C for 
24 h and analyzed via Full Scan MS. Method specifics for both full scan MS and product ion MS-
MS may be found in Appendix 6. 
 Identified adducts were further characterized with regards to kinetics of formation and 
exposure-response relationships. Kinetics of adduction was assessed by incubating 0.02 mg/mL 
each peptide with excess HN-2 or HN-3 and analyzing triplicate samples once every 30 min  for 8 
h. Exposure-response relationships between HN concentration and adduction level was performed 
by 24 h incubation of triplicate samples of 0.02 mg/mL model peptide with various molar ratios 
of HN-2 or HN-3 (i.e., 1:1, 10:1, 25:1, 50:1, 100:1 and 150:1 molar excess HN). Samples were 
run via full Scan MS (method specifics as seen in Appendix 6). 
 Finally, adduct stability at 37°C was assessed over a three-week analysis period. 
Triplicate 1 mL 0.02 mg/mL samples were incubated with 100:1 molar excess of HN-2 or HN-3 
for 3 h. Following incubation, unreacted HN was removed from the samples via solid phase 
extraction (SPE) cleanup using Empore C18 SD cartridges (3 mL). Cartridges were first 
conditioned with 1 mL methanol and equilibrated with 500 μL 0.1% TFA in 70% acetonitrile. 
Samples were then loaded onto the cartridge, washed with 500 μL 0.1% TFA in HPLC water, and 
eluted using 500 μL 0.1% TFA in 70% acetonitrile. The acetonitrile was evaporated from the 
samples using a nitrogen blow-down system, leaving approximately 300 μL of eluent. Sodium 
phosphate buffer (10 mM, pH 7.4) was added to the samples to bring the volume back to 1 mL. 
For each time point assessed (3 h, 24h, 1 week, 2 weeks, and 3 weeks), an aliquot of each sample 
was removed, while the remaining sample was kept at 37°C during the three-week analysis 
period. Samples were analyzed via full scan MS (method specifics as seen in Appendix 6).  
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3.3. Full Protein Adduction Studies 
Target proteins Hb and HSA were analyzed both as intact proteins and via digestion of 
the protein into peptides so as to identify specific adducted residues. Intact proteins were 
analyzed via direct injection of the protein (no column separation) using a deconvolution 
algorithm within the Agilent BioConfirm software package. Deconvolution parameter specifics 
are seen in Appendix 5. Deconvolution and analysis of intact proteins allowed for not only 
confirmation of protein molecular weight, but also an indication of approximately how many 
adducted residues may be present on the proteins after incubation with HN-2 and HN-3. 
Confirmation of the number of adducted residues, however, was performed using MS-MS 
analysis of digested proteins.  
 Full protein digestions were performed as specified in Wisniewski et al.125 Sample 
preparation utilized 10 kilodalton (kDa) cutoff spin filters in order to remove excess reagents, 
exchange buffer, and to allow for the removal of digested peptides from non-digested protein. 
Reduction of protein disulfide bonds was performed by adding tris(2-carboxyethyl)phosphine 
(TCEP) at a final concentration of 50 mM and incubating at room temperature for 1 h. Excess 
TCEP was removed via centrifugation with the 10 kDa spin filters, followed by cysteine 
alkylation via addition of iodoacetamide at a final concentration of 50 mM. Protein digestion was 
performed using trypsin at an enzyme:protein ratio of 1:10. Following protein digestion overnight 
at 37°C, 10 kDa spin filters were utilized to collected digested peptides, while leaving any 
undigested protein and the digestion enzyme in the spin filter. Collected tryptic peptides were 
then subject to SPE cleanup using Supelco Discovery DSC-18 SPE cartridges (1 mL). Cartridges 
were conditioned with 1 mL methanol and equilibrated with 1 mL 0.1% TFA in 70% acetonitrile. 
The collected tryptic peptides were loaded onto the SPE cartridge and washed with 500 μL 0.1% 
TFA in HPLC water. Peptides were eluted from the cartridge using 500 μL 0.1% TFA in 70% 
acetonitrile, and a nitrogen blow-down system was used to evaporate the acetonitrile, leaving 
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approximately 100 μL of eluent. Eluents were analyzed via LC-Q-TOF-MS-MS. Method 
specifics for Hb and HSA analysis are as seen in Appendix 6.  
 Data analysis of the digested proteins was performed using Agilent BioConfirm software 
package. The software package identifies compounds from the auto MS-MS data, and uses 
protein sequences added by users to match the sequence to compounds found in the data file, 
factoring in complete digestion, incomplete digestion, and predicted amino acid modifications. 
Analysis method specifics for the identification of compounds and sequence matching may be 
found in Appendix 5. All matched results obtained from BioConfirm were assessed for accuracy 
based on theoretical MS-MS fragmentation and for reproducibility among multiple samples. 
 To identify the lowest molar ratio of HN:protein necessary to produce adduction (and 
thus, the most reactive site(s) of adduction), protein samples (30 μL 8 mg/mL lyophilized protein 
in 50 mM AmBic, pH 8.0) were incubated with varying molar excess of HN (1:1. 10:1, 25:1, 
50:1, 100:1, 150:1, and 200:1). Samples were allowed to incubate at 37°C for 3 h, then excess 
HN was removed and samples were concentrated using 10 kDa spin filters. Samples were then 
analyzed via direct (i.e., column-free) injection analysis on LC-Q-TOF-MS. Peaks were 
deconvoluted using BioConfirm analysis software in order to identify which concentration ratio 
would produce a noticeable mass shift corresponding to approximately one adduction by HN-2 or 
HN-3. This ratio was then utilized in samples that were digested via the protocol described above, 
and adduction site(s) identified via analysis of sample data using BioConfirm software.  
 Identification of protein adducts was done by incubating triplicate samples (30 μL 8 
mg/mL lyophilized protein in 50 mM ammonium bicarbonate (AmBic), pH 8.0) with HN-2 or 
HN-3 (100× HN for Hb, 50× HN for HSA) at 37°C for 3 h. Samples placed in 10 kDa spin filters 
and washed twice with 200 μL HPLC water to concentrate the sample and to remove unreacted 
HN. The sample was split into two aliquots – the first (approximately 10 μL) was diluted to 
approximately 1 mg/mL and analyzed via direct injection, and the second (approximately 30 μL) 
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was digested to identify specific adducted residues. BioConfirm was utilized to analyze digest 
samples by matching identified compounds with the protein sequence, allowing for compounds to 
be complete digest fragments, incomplete digest peptides, or peptides with predicted 
modifications. Any peptides identified with a predicted modification of HN-2 or HN-3 were 
confirmed by analyzing MS-MS data produced and comparing the peaks to expected peptide 
fragmentation as identified by Protein Prospector (http://www.prospector.ucsf.edu)126 Identified 
adducts were determined as true adducts if present in all three triplicates at the same retention 
time with MS-MS confirmation in at least two of the three samples (adduct identification criteria 
further discussed in Section 4.2). 
 Finally, the stability of identified adducts was performed over a three-week analysis 
period. Seven samples consisting of 200 µL 8 mg/mL lyophilized protein (HSA or Hb) were 
utilized for these experiments. For Hb stability, triplicate samples of Hb were incubated with 200 
µL HN-2 or HN-3 for a final concentration of 100:1 molar excess HN (as compared to the protein 
concentration) and one control protein sample incubated with 200 µL 50 mM AmBic, pH 8.0. For 
HSA, triplicate samples of protein were incubated with 200 µL HN-2 or HN-3 for a final 
concentration of 50:1 molar excess HN (as compared to the protein concentration), with a final 
sample serving as a protein control, incubated with 200 µL 50 mM AmBic, pH 8.0. Protein 
samples were incubated for 3 h at 37ºC, followed by excess HN removal and sample 
concentration via 10 kDa spin filters. AmBic (50 mM, pH 8.0) was utilized to bring the recovered 
protein volume back to 200 µL after cleanup. To each sample, 1 µL of protease inhibitor cocktail 
(details as seen in Appendix 8) was added to prevent enzymatic protein breakdown during the 
analysis period. For each analysis time point (3 h, 24 h, 1 week, 2 week, and 3 week), a 30 uL 
aliquot was removed from the original sample for tryptic digestion (as described above). The 
original samples incubated at 37ºC and were vortexed daily during the analysis period. 
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3.4. Whole Blood Studies 
 As a proof of concept study, human whole blood samples (obtained from Bioreclamation, 
Inc.) were incubated with HN-2 and HN-3 and the target proteins (Hb and HSA) were isolated 
and analyzed for adducts identified in Task 3.3. One mL of whole blood (heparinized) was 
incubated with HN-2 or HN-3 (dissolved in 40 μL HPLC water) at a final concentration of 2 mM 
for 2 h under gentle shaking.  Following incubation, whole blood samples were centrifuged at 
1000 × g for 30 min at 4ºC so as to separate the plasma (containing HSA) from the red blood cells 
(containing Hb) and remove leukocytes and platelets.  
 Serum albumin extraction was performed on separated plasma in two ways – the first was 
via affinity chromatography extraction, and the second as described in Bechtold et al.127 Affinity 
chromatography extraction of HSA was performed using HiTrap Blue HP affinity columns (1 
mL) (GE Healthcare, Inc.). Extracted plasma was diluted to twice the original volume using 40 
mM sodium phosphate buffer, pH 7.0 so as to match the composition of the manufacturer-
suggested binding buffer (20 mM sodium phosphate, pH 7.0). First, the columns were washed 
with 10 volumes (10 mL) of binding buffer using a syringe attached to the top of the column. The 
diluted plasma sample was then added to the affinity column slowly (approximately 1 mL/min) 
via syringe. The column was then washed with 10 mL of binding buffer, and the sample was 
eluted with 10 mL of elution buffer (20 mM sodium phosphate buffer, 2 M NaCl, pH 7.0). The 
collected eluate was then concentrated to 500 μL using Amicon 10 kDa spin filters, followed by 
buffer exchange to 50 mM AmBic pH 8.0. 
 For the precipitation protocol of HSA extraction, an equal volume of 0.5 M CaCl2 was 
added to the plasma and allowed to incubate at 4ºC overnight. After incubation, the sample was 
centrifuged at 900 × g for 20 min at 4ºC. The supernatant was extracted from the sample, 
discarding the precipitated fibrinogen. Four volumes of 0.9% (w/v) NaCl was added to the 
recovered supernatant to salinate the sample. Nine volumes of acidic alcohol (0.02 M HCl in 
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100% ethanol) was added dropwise to the salinated supernatant and incubated at 37ºC for 30 min. 
Samples were then centrifuged at 650 × g for 30 minutes. The supernatant was removed and the 
precipitate (globin) was discarded. To the recovered supernatant, 0.2 M sodium acetate was added 
at 1/10th the volume of the supernatant, and the solution was allowed to incubate for 15 min at 
room temperature. The sample was centrifuged at 650 × g for 5 min. The supernatant was 
discarded, leaving behind the precipitated HSA. Purified HSA was then washed with 5 mL of 
acetone, followed by 5 mL of diethyl ether, centrifuging at 650 × g for 5 min for each wash. The 
supernatants were discarded and the solid was allowed to dry. Once dry, the solid was weighed 
and a solution of 10 mg/mL was created in 50 mM AmBic, pH 8.0. For each sample, 30 µL was 
removed and digested via the protocol above. An additional aliquot was removed to create a 1.0 
mg/mL sample for direct injection and deconvolution analysis (MS parameters as seen in 
Appendix 6, deconvolution parameters as seen in Appendix 5). 
 Hemoglobin precipitation was performed on the isolated red blood cell fraction as 
reported in DeCaprio et al.,128 with some modifications. Red blood cells were washed three times 
with 310 mOsm Tris buffer, pH 7.6 at 1000 x g for 30 min at 4ºC. After the third wash, cells were 
resuspended in 310 mOsm Tris buffer to 50% hematocrit. Cells were then lysed by forceful 
syringe injection of six volumes of 20 mOsm Tris buffer, pH 6.7. Lysed cells were centrifuged at 
20,000 × g for 40 min at 4ºC. The hemolysate was removed and precipitate was discarded. The 
hemolysate was then brought to 0.2 M ascorbic acid and was added dropwise to 20 volumes of 
ice cold acetone and allowed to incubate overnight at -20ºC. The following day, samples were 
centrifuged at 1000 × g for 10 min at 4ºC. The supernatant was discarded and the precipitated Hb 
was washed twice with 5 mL of ice cold acetone by centrifuging at 1000 × g for 10 min at 4ºC. 
The precipitated Hb was allowed to dry. Once dry, the protein was weighed and a 10 mg/mL 
solution was created in 50 mM AmBic, pH 8.0. For each sample, 30 µL of sample was removed 
for tryptic digest (as described above). In addition, a 1.0 mg/mL sample was also created for 
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direct injection and deconvolution analysis (MS parameters as described in Appendix 6, and 
deconvolution parameters as described in Appendix 5). 
 To assess the overall success and purity of the described protein extractions, HSA and Hb 
were extracted from triplicate whole blood samples not previously incubated with HN via the 
extraction methods described above. Proteins were dissolved in 50 mM AmBic pH 8.0 to create 4 
mg/mL samples and run via LC-Q-TOF-MS. Chromatographic separation of whole proteins was 
performed on an Agilent ZORBAX StableBond 300SB-C8 column (100 mm × 2.1 mm, 1.8 μm 
particle size). Extracted protein samples were compared to lyophilized proteins (4 mg/mL 
solutions in AmBic, pH 8.0) for a general assessment of purity and for retention time (RT) 
comparison. In addition, peaks were deconvoluted (method specifications as seen in Appendix 5) 
and compared to expected molecular weights for Hb and HSA. Method specifics for C8 
separation of whole proteins may be found in Appendix 6. 
 
3.5. In Vitro Metabolism of Nitrogen Mustard Therapeutics 
 For the metabolic analysis of the therapeutic nitrogen mustards Chlorambucil, 
Cyclophosphamide, and Melphalan, liver homogenate in vitro metabolic systems were utilized to 
determine whether metabolism products of these three drugs produced the same adducts as their 
chemical weapon counterparts (HN-2 and HN-3). The two biotransformation enzyme systems 
utilized for this study were human liver microsomes (HLM) and the S9 fraction (S9), as these two 
fractions are frequently utilized to represent the metabolic activities of the hepatic 
microenvironment, thus providing a global picture of Phase I liver metabolism of these drugs. 
The assay components for these in vitro assays are described in Table 4 and were adapted from 
Schneider and DeCaprio.129  
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Table 4: Components of in vitro metabolic system. 
 All metabolic studies were performed in 10 mM SPB at pH 7.4 so as to mimic human 
physiological conditions within the assay. The buffer, substrate, and enzyme system were 
combined and pre-incubated at 37°C for 5 min before adding the assay cofactors (MgCl2 and 
NADPH) to the mixture. Samples were allowed to incubate at 37°C for 1.5 h. Samples were then 
quenched with ice cold 6% (v/v) acetic acid in acetonitrile and centrifuged at 4°C for 30 minutes 
at 15,000 × g so as to pellet assay proteins. The supernatant was then removed for analysis via 
LC-QQQ-MS. SIM-MS of expected adduct masses for each trapping peptide (method specifics as 
seen in Appendix 6) was utilized. The presence or absence of adducts was confirmed by 
comparing SIM results of the therapeutic mustards to adducts formed with the trapping peptides 
incubated with HN-2 or HN-3, which are known to form without the need for metabolic 
activation and should therefore form in the presence of metabolic systems. If no peak was present 
at the same retention time as compared to the control samples, it was concluded that the drug did 
not metabolize into a reactive intermediate that forms the same adduct(s) as HN-2 or HN-3. 
 
3.6. Quantum Mechanical Calculations 
 Calculations to determine the chemical potential (μ), chemical hardness (η), and 
reactivity index (ω-) were performed first by determining the EHOMO and ELUMO of the reactive 
nucleophiles and hypothesized reactive electrophiles from the present study. Energies for each 
HLM S9
Buffer
Substrate
Enzyme 2.0 mg/mL HLM 2.0 mg/mL S9
Activating Cofactor
Non-activating Cofactor
Metabolic System
200 μM positive control (HN-2 or HN-3), 
chlorambucil, cyclophosphamide, or melphalan
2.0 mM NADPH
3.0 mM MgCl2
Component
10 mM sodium phosphate buffer, pH 7.4
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compound were determined by optimizing the structure geometry using Chem 3D Ultra software 
(Version 8, CambridgeSoft Corporation) and exported into Gaussian 03 software (Gaussian, Inc.). 
130 EHOMO and ELUMO energies were calculated using a B3LYP function with 6-31G* basis set. 
Based on these optimized energies, calculations for chemical potential, chemical hardness, and 
reactivity index were performed based on HSAB Theory as presented in Section 2.3 (Equations 
1-3). 
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4. RESULTS AND DISCUSSION  
4.1. Model Peptide Adduct Screening 
4.1.1. HN-2/HN-3 Adduction to AcPAACAA 
 Previous work involving protein adduction to nitrogen mustards such as HN-2 and HN-3 
has demonstrated their ability to adduct to Cys;41,93,95 therefore, HN-2 and HN-3 adduction to the 
model peptide AcPAACAA was used as a point of reference for adduction to Lys (AcPAAKAA) 
and His (AcPAAHAA) as alternative sites. Adduction of HN-2 to AcPAACAA was observed via 
full scan LC-QQQ-MS by the appearance of a peak at m/z 664 daltons (Da), corresponding to a 
mass increase of 119 Da, the expected adduction mass increase for HN-2. Furthermore, the 
isotopic ratio of the adducted product was consistent with that of one chlorine atom present, as 
would be expected with HN-2 adduction. In addition, MS-MS confirmation of the adduct was 
performed via Product Ion Scan LC-QQQ-MS. Figure 12 demonstrates the presence of the 
AcPAACAA adduct peak as compared to a control spectrum, in addition to the isotopic ratio of 
the product. Further confirmation of HN-2 adduction is demonstrated in the MS-MS spectra for 
the adduct peak. The MS-MS spectrum shows fragments corresponding to expected peptide 
fragmentation, in addition to a peak corresponding to the HN-2 aziridinium (Az) ion (m/z 120 
Da). When compared to the parent peptide MS-MS, the fragment corresponding to the 
aziridinium ion is missing. This peak, therefore, is indicative of HN-2 adduction. 
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Figure 12: HN-2 adduction to AcPAACAA. (A) EIC of parent [red] and adducted [green] peptide. 
(B) MS spectrum of adduct peak, demonstrating chlorine isotope. (C) MS-MS spectrum of adduct 
peak. Precursor ion in seen in blue; adducted Cys in red. (D) Fragmentation diagram of MS-MS 
data, with adducted Cys residue structure shown. 
 
 Adduction of AcPAACAA to HN-3 occurred via a similar manner – incubation of 
AcPAACAA with excess HN-3 revealed a product peak with a mass increase of 149 Da as 
compared to the parent peptide. This product is consistent with HN-3 adduction in which one 
chlorine remained attached to HN-3 and the second chlorine was lost via hydrolysis. This 
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conclusion is further supported by the isotopic ratio of the observed product, consistent with one 
chlorine present within the adduct molecule, as can be seen in Figure 13. 
 
Figure 13: HN-3 adduction of AcPAACAA. (A) EIC of parent [red] and adducted [green] peptide. 
(B) MS spectrum of adduct peak, isotope ratio demonstrates one chlorine attached. (C) MS-MS 
spectrum of adduct. Precursor ion highlighted in blue, adducted Cys in red. (D) Fragmentation 
diagram of MS-MS data, with adducted Cys structure shown. 
 
 The exposure-response relationship of HN-2 and HN-3 incubation to AcPAACAA was 
also determined as a reference for future studies. Full scan analysis demonstrated that the lowest 
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molar ratios for observable adduction were 100:1 molar excess for HN-2 and 50:1 molar excess 
for HN-3. It is important to note that, throughout these adduction studies, complete adduction of 
the model peptides was never observed, nor was it expected to occur based on literature 
reports.131 Based on this data, a 100:1 ratio of nitrogen mustard:peptide ratio was selected for 
AcPAACAA adduction in further experiments. 
 
4.1.2. HN-2/HN-3 Adduction to AcPAAKAA 
 Adduction of HN-2 to the Lys residue of AcPAAKAA was observed by the appearance 
of a peak with m/z 711 Da following HN-2 incubation. This corresponds to a mass increase from 
the parent peptide of 141 Da, or an HN-2 adduct (119 Da) with a sodium ion (+22 Da). 
Electrospray ionization is known to produce sodium adducts in sodium phosphate buffer, which 
may be more abundant than traditional M+H ions in certain cases. This assignment can be further 
confirmed by analysis of the MS spectrum (Figure 14) of the adduct peak more closely. The 
appearance of the HN-2 adduct without the sodium (m/z 689 Da) is present, albeit at a lower 
intensity. In addition, the isotopic ratios demonstrate the presence of one chlorine attached to the 
product molecule, similar to what was seen with Cys adduction.  
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Figure 14: HN-2 adduction to AcPAAKAA. (A) EIC of the parent [red] and adducted [green] 
peptide; (B) MS spectrum of adduct peaks, with isotopic ratios consistent with one chlorine attached; 
(C) Labeled MS-MS spectrum of the Lys-HN-2 adduct (precursor ion in blue, adducted Lys in red). 
(D) Fragmentation diagram of MS-MS data, with adducted Lys structure shown. 
 
 Adduction of HN-3 to AcPAAKAA occurred in a similar fashion. After HN-3 incubation, 
a peak corresponding to m/z 741 was observed, corresponding to a mass increase of 171 Da from 
the parent peptide. This mass increase is consistent with a sodium adduct (+22 Da) of the HN-3 
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adduction product (149 Da), similar to what was observed for Cys adduction. This can be further 
confirmed via the MS spectrum of the product, whose isotopic ratio is consistent with one 
chlorine present in the molecule (Figure 15). 
 
Figure 15: HN-3 adduction to AcPAAKAA. (A) EIC of parent [red] and adducted [green] peptide. 
(B) MS spectrum of adduct peak, demonstrating isotopic ratios consistent with one chlorine present. 
(C) Labeled MS-MS spectrum. Precursor ion in blue, adducted Lys in red. (D) Fragmentation 
diagram based on MS-MS data, with adducted Lys residue structure shown. 
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 The exposure-response relationship of adduction to AcPAAKAA was determined for 
HN-2 and HN-3. In both cases, the lowest observed excess ratio of nitrogen mustard was 100:1, 
which was consistent to what was seen with AcPAACAA adduction. For this reason, the 100:1 
molar excess of HN was utilized for Lys adduction in further studies. 
 
4.1.3. HN-2/HN-3 Adduction to AcPAAHAA  
 HN-2 adduction to AcPAAHAA was determined by the appearance of an adduct peak 
with m/z 720 Da, corresponding to a mass increase of 141 Da. As with AcPAAKAA adduction, 
sodium adducts (+22 Da) of the HN-2 adduct (mass increase of 119 Da) were observed, as can be 
seen in the analysis of the MS spectra in Figure 16. As seen previously, isotopic ratios of the 
adduct peak are consistent with one chlorine attached to the product. 
 A similar adduction pattern was seen with HN-3 (Figure 17). Following incubation of 
HN-3 with AcPAAHAA, an adduct peak of m/z 750 Da was observed, a mass increase of 171 Da 
from the parent peptide. This corresponds to HN-3 adduction (149 Da) of the peptide with a 
sodium adduct (+22 Da). As with previously identified adducts, the isotopic ratio of the adduct 
peak is consistent with one chlorine attached to the molecule.  
 Finally, the exposure-response relationship of adduction to AcPAAHAA was determined. 
For both HN-2 and HN-3, the lowest observed molar excess of HN was 100:1 nitrogen 
mustard:peptide, demonstrating consistent results as seen with both AcPAACAA and 
AcPAAKAA. As with the other two peptides, 100:1 molar excess of HN was selected as the ratio 
for His adduction for further studies. 
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Figure 16: HN-2 adduction of AcPAAHAA. (A) EIC of parent [red] and adducted [green] peptide. 
(B) MS spectrum of adduct, demonstrating chlorine isotope. (C) MS-MS spectrum of adduct. 
Precursor ion in blue, adducted His in red. (D) Fragmentation diagram based on MS-MS data, with 
adducted His residue structure shown. 
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Figure 17: HN-3 adduction of AcPAAHAA. (A) EIC of parent [red] and adducted [green] peptide. 
(B) MS spectrum of adduct, demonstrating chlorine isotope. (C) MS-MS spectrum of adduct. 
Precursor ion in blue, adducted His in red. (D) Fragmentation diagram based on MS-MS data, with 
adducted His residue structure shown. 
 
4.1.4. Specificity of Identified Adducts based on Precursor Incubations 
 All three model peptides were incubated with HN-2 and HN-3 precursors N-
methyldiethanolamine and triethanolamine (Figure 18) to assess whether adducts would form 
with these compounds. These ethanolamine compounds are not only the synthetic precursors to 
HN-2 and HN-3, but they are also the hydrolysis products of these compounds that may be found 
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in biological specimens. This task was therefore important to assess the usefulness of these 
adducts as potential exposure biomarkers – should the same adducts form with these precursor 
molecules, these adducts would not be specific to HN-2 or HN-3 exposure.  
N
OH OH
N
OH OH
OH
N-methyldiethanolamine triethanolamine
 
Figure 18: Structure of the HN-2 and HN-3 precursors N-methyldiethanolamine (HN-2) and 
triethanolamine (HN-3). 
 
 Incubation of the ethanolamine compounds with the model peptides for 24 h did not 
produce any adducts on the model peptides; as such, identified adducts are specific to HN-2 and 
HN-3 exposure when compared to their ethanolamine precursors. 
 
4.1.5. Formation Kinetics of Model Peptide Adducts 
 The kinetics of adduction for both HN-2 and HN-3 to AcPAACAA produced similar 
results. Adducts to HN-2 and HN-3 were observed within 30 min of incubation with 
AcPAACAA. For HN-2, the amount of adduct increased steadily until approximately 4 h, after 
which a steady-state of adduct was obtained. In contrast, HN-3 adduction reached a plateau 
within about 2 h, after which a slight decrease in adduct was observed. This was most likely a 
result of the hydrolysis of the HN-3 adduct (loss of –Cl to –OH), which occurs in aqueous 
environments.132 This hydrolysis would decrease the detected amount of chlorinated adduct and 
thus lower the ratio observed. Figure 19 demonstrates the kinetics of formation for HN-2 and HN-
3 over an 8 h analysis period. 
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Figure 19: Relative kinetics of formation of HN-2 [red] and HN-3 [pink] adducts to AcPAACAA. 
Error bars represent standard deviation obtained from triplicate samples. 
 
 HN-2 adducts with AcPAAKAA were present within 30 min of incubation, and 
demonstrated a steady increase until approximately 3 h, after which a steady-state of adduction 
occurred. In contrast, adducts of HN-3 were not observed until 1 h after incubation. However, as 
with HN-2, adduction demonstrated a steady increase until approximately 3-3.5 h, after which a 
steady state was achieved (Figure 20). 
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Figure 20: Relative kinetics of formation of HN-2 [dark blue] and HN-3 [light blue] adducts to 
AcPAAKAA. Error bars represent standard deviation obtained from triplicate samples. 
 
 The kinetics of adduction of HN-2 and HN-3 for AcPAAHAA followed a similar pattern 
to what was seen with AcPAAKAA (Figure 21). For HN-2, adduction was observed after 30 min 
of incubation with HN-2, and reached a steady state of adduction at approximately 3 h. Adduction 
to HN-3 was not observed until 1 h after incubation, with a steady-state reached after 4 h. 
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Figure 21: Relative kinetics of formation of HN-2 [dark green] and HN-3 [light green] adducts to 
AcPAAHAA. Error bars represent standard deviation obtained from triplicate samples. 
 
 As mentioned previously, adduction of HN-2 and HN-3 to AcPAACAA was utilized as a 
comparison point for adduction to AcPAAKAA and AcPAAHAA. While adduction of HN-2 and 
HN-3 was observed on all three model peptides, a definite contrast can be seen when comparing 
the relative kinetics of adduction to Cys as compared to Lys and His. As can be seen in Figure 22, 
the rate of adduct formation of HN-2 and HN-3 with AcPAACAA (red) is much higher than 
AcPAAKAA (blue) and AcPAAHAA (green). This is to be expected, as Cys is considered a 
“softer” nucleophile and is therefore likely to be more reactive towards electrophilic adduction 
than the “moderately hard” Lys and His. However, as nitrogen mustards (specifically, 
chemotherapeutic agents containing the nitrogen mustard group) have been documented to adduct 
to nitrogen centers,105 it was expected that adduction of HN-2 and HN-3 to nitrogen-containing 
side chains on Lys and His residues would also occur. Also noted in Figure 22 is a reversal in the 
kinetics of His and Lys between HN-2 and HN-3 adduction – for HN-2, His adduction is more 
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prominent, whereas the opposite is true for HN-3. This may be due to the steric bulk of the HN-3 
Az species adducting to the His imidazole, which is not as easily accessible as the Lys amine 
group. Finally, the slight lag apparent in the adduction of HN-3 to Lys and His (as compared to 
HN-2) is most likely due to the increased reactivity of HN-2 over HN-3, since the hypothesized 
reactive species for HN-3 (HN-3 Az with one hydrolyzed Cl) may take longer to form than the 
reactive HN-2 species.  
 
Figure 22: Comparison of formation kinetics for HN-2 (a) and HN-3 (b) for AcPAACAA [red], 
AcPAAKAA [blue], and AcPAAHAA [green]. 
 
 With the exception of the relative kinetics of formation, the results obtained from the 
adduction of HN-2 and HN-3 to all three model peptides were consistent. A general steady state 
of adduction was achieved for all six adduct products at approximately 3 h; therefore, for later 
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experiments, a minimum of 3 h was utilized for adduction. In addition, the lowest observed ratio 
of excess HN was 100:1 in five of six instances; therefore, later work involving peptides utilized 
this molar excess ratio of HN:peptide. The consistency observed for the model peptide studies 
suggest that, when scaled up to full proteins, HN-2 and HN-3 adduction would be expected to 
occur on Lys and His residues in addition to the previously demonstrated Cys adduction.   
 
4.1.6. Stability of Model Peptide Adducts 
 The stability of HN-2 and HN-3 adducts was observed over a three-week incubation 
period. Throughout this period, samples were kept at physiological conditions (pH 7.4, 37ºC) to 
mimic the stability of these adducts in the body. During the analysis process, the products 
described above (herein described as “-Cl adducts,” as seen in Figure 23) were monitored via full 
scan MS. In addition, products corresponding to hydrolysis of all chlorine atoms present on the 
adduct (herein described as “-OH adducts”) were also monitored. As these adducts were present 
in aqueous environment for an extended period of time, previous work regarding nitrogen 
mustard adduction133 suggested that –OH adducts may be more prominent than the previously 
identified –Cl adducts. All –OH adducts were confirmed via MS-MS analysis and RT matching 
from previous analysis (Appendix 6). 
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Figure 23: Structures of identified peptide adducts; (A) = Cys; (B) = Lys; (C) = His. 
 For HN-2, the –Cl adducts for all three model peptides were detected throughout the 
three-week analysis period. In addition,–OH adducts were observed starting 24 h after initial HN-
2 incubation. All three –Cl adducts exhibited a decrease in signal as the analysis period 
progressed, paired with a corresponding increase of –OH adduct over time. As mentioned 
previously, this was expected based on previously published results, and may suggest that the –
OH adducts may be more relevant for full protein and long term exposure biomarker studies. 
 For HN-3, the –Cl adducts were present for all three products for the first two time points 
(3 h and 24 h); however, they were not detected at the one week time point for AcPAACAA and 
AcPAAHAA. Chlorinated adducts of AcPAAKAA were present throughout the three-week 
analysis period, but at substantially lower abundance than the observed –OH adducts. Despite the 
fact that the –Cl adducts were not present after 24 h for AcPAACAA and AcPAAHAA, the –OH 
adducts were observed during the three week analysis period. An HN-3 molecule containing two 
bulky side chains is more likely to experience steric hindrance; therefore, it may hydrolyze more 
rapidly as compared to the less bulky HN-2 adduct. The –Cl adduct attached to AcPAAKAA may 
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persist longer due to the decreased steric stress of adduction on the long side chain of Lys as 
compared to the smaller, more hindered chains of Cys and His. Regardless, these results also 
suggest that the fully hydroxylated adducts may be more relevant to monitor for full protein 
studies, in which steric factors will play a much larger role than they do in model peptides. 
Results for the stability of both HN-2 and HN-3 adducts can be seen in Figure 24. 
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Figure 24: Stability of HN-2 (a-c) and HN-3 (d-f) over three weeks. (a, d): Adduction of AcPAACAA. 
(b, e): Adduction of AcPAAKAA. (c, f): Adduction of AcPAAHAA. 
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4.1.7. Discussion 
 Results of characterization of HN-2 and HN-3 adduction to Lys and His residues in the 
model peptides AcPAAKAA and AcPAAHAA were compared to results of adduction at a known 
reactive moiety (Cys; AcPAACAA). The results from the present work confirm previous reports 
demonstrating that HN-2 and HN-3 will adduct with Cys residues. More importantly, however, 
this work also demonstrates that adduction of these nitrogen mustards can also occur at Lys and 
His, a finding that was fully confirmed via isotopic ratios and MS-MS results. While adduction 
may occur more readily at Cys residues in the model peptide system employed here, adducts to 
Lys and His were observed to be equally stable as Cys adducts over a three week analysis period. 
This was particularly true for the fully hydroxylated adducts, which is the focus of full protein 
adduction studies described later.  
 It is important to note that the results obtained here are representative of a model system 
in which several factors (most notably steric) have been carefully controlled so as to assess 
adduction potential at the nucleophilic sites of interest (Cys, Lys, and His) in the absence of 
higher order influences. It is recognized that the site-specific kinetics of formation and 
interactions between nucleophilic sites and the electrophilic HN intermediates observed in this 
task, while important, may not be identical to those obtained for full proteins. This prediction is 
based on the previously described mediators of adduction in proteins, including steric factors in 
addition to electronic microenvironments surrounding a potential adduction site (discussed in 
section 2.3). As such, the observation that Lys and His adduction were comparable with Cys in 
model systems would not necessarily guarantee that the same results will be obtained in full 
proteins. 
 For initial adduct determination and molar ratio studies, Full Scan MS mode was selected 
instead of other, likely more sensitive methods (such as SIM or MRM). Full Scan MS was 
determined to be more applicable to the planned later experiments in which full proteins would be 
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incubated with HN-2 and HN-3. For these reasons, a higher molar excess than would be likely to 
occur in vivo was selected to confirm adduction. It is believed that a lower ratio could have been 
utilized with the more sensitive MS approaches listed above; however, as the purpose of this 
study was primarily to demonstrate that adduction could occur with lysine and histidine in 
principle, it was deemed appropriate for this task. 
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4.2. Full Protein Adduction Studies 
 The ultimate goal of this work was to identify novel, alternative protein adduct based 
biomarkers of exposure of HN-2 and HN-3, specifically on Lys and His residues. As these 
adducts have not been previously documented, it was of extreme importance that a high level of 
discrimination be used before a suspected adduct could be positively identified. Therefore, a 
series of criteria was implemented so as to maximize confidence in the results presented. While 
these strict criteria may mean that other adducts could have been falsely eliminated, they lend a 
high level of specificity to the results presented herein. 
 The software utilized for the identification of adducts was Agilent BioConfirm v. 5.0 
(Specific parameters utilized for analysis may be found in Appendix 5). With this software, users 
can input post-translational modifications (whether standard within the program or in-house 
additions) to a matching algorithm, which will take a given protein sequence and the user-
specified modifications and selectively match the data obtained from the instrument to possible 
peptides. The software provides a large amount of information, including a mass difference from 
the theoretical fragment and the location of any modifications identified within the peptide. While 
this matching algorithm is useful, at times the software can make assignments that do not follow 
certain rules. For example, a modification may be placed on the terminal Lys of a tryptic peptide, 
which would not be possible since trypsin would not be able to cleave at that location if the Lys 
were modified as a result of steric interference from the adduct moiety. The software may also 
place several modifications on adjacent residues, which may not be possible due to the potential 
steric strain on the molecule. These examples are a consequence of the “force fit” mechanism that 
the software employs.  
 For these reasons, it was important to follow up any software-identified adduct with 
independent MS-MS data support. For the full protein work, the MS-MS fragmentation for a 
potential adducted peptide was confirmed manually using theoretical fragmentation data obtained 
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from Protein Prospector,126 in which additional fragments besides b and y could be utilized for 
higher confidence identification. BioConfirm is programmed to label b and y fragments; however, 
it will at times miss some (i.e., may not label a fragment as b or y despite its concordance with 
Protein Prospector’s theoretical peak list), and does not consider internal fragmentation or a 
fragments, which are also commonly encountered with low-energy CID.134 Consequently, MS-
MS data were also analyzed by manual techniques to confirm a true positive identification. 
 Finally, it was also important to ensure that an identified adduct was reproducible in 
multiple replicate samples. The Q-TOF MS-MS method employed Auto MS-MS, meaning that 
(based on manufacturer-recommended settings) the three most abundant ions in each scan were 
selected to trigger MS-MS analysis. However, because of the variability of individual sample 
digests, a particular ion may have triggered MS-MS in one sample, but not in another. For this 
reason, it was important to set limits of acceptable variation when looking at multiple samples, 
balanced as much as possible with a low false positive rate. 
 When all of these factors were taken into consideration, the following rules were 
followed in order to ensure that a high level of confidence was present in the identification of 
adducts on intact model proteins: 
 For each experimental run, triplicate samples of each condition (HN-2 or HN-3) were 
analyzed for reproducibility. 
 A control protein sample (incubated in the absence of HN-2 or HN-3) was prepared and 
utilized to eliminate false positives identified by the software. False positives were 
defined as any peptide in the control sample that the software errantly determined to 
contain a HN modification. False positives were located within the software generated 
compound (ion) list for the HN-2 and HN-3-incubated samples, and if the description 
(same peptide and adduction site) and retention time (RT) matched with a previously 
designated false positive, they were eliminated from further analysis. 
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 In each sample, any compound that was determined by the software to have an HN 
modification and MS-MS support was analyzed by hand. Theoretical peak lists for the 
MS-MS spectra were obtained from Protein Prospector (specific search parameters are as 
seen in Appendix 7). An MS-MS fragment was considered positively identified if peak 
mass matching between empirical data and theoretical Protein Prospector data was 
concordant within one-tenth of a Dalton. If a fragment mass deviated by more than one-
tenth of a Dalton from the theoretical mass, it remained in the pool of candidate peptides 
if a positively identified second ion was present for support (For example, if the y5 ion 
deviated from theory by more than one-tenth of a Dalton, it would only be labeled if a 
supporting ion, such as y5+2 could be positively identified within the MS-MS spectra).    
 Within each experiment, the triplicates were compared for consistency of identified 
adducts. In each sample, an adduct could be either 1) present in the peak list with 
confirmed MS-MS data, 2) present in the peak list, but without MS-MS data, 3) present 
in the peak list, but at a different RT, or 4) not present. Table 5 below demonstrates 
various scenarios that could be obtained from triplicate samples, and what requirements 
were necessary for a positive identification in each case. 
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Condition Positive 
Identification? Sample 1 (S1) Sample 2 (S2) Sample 3 (S3) 
MS-MS confirmation MS-MS confirmation MS-MS confirmation Yes 
MS-MS confirmation MS-MS confirmation 
Cpnd at same RT as S1 
and S2; no MS-MS 
collected by software 
Yes 
MS-MS confirmation 
Cpnd at same RT as S1; 
no MS-MS collected by 
software  
Cpnd at same RT as S1; 
no MS-MS collected by 
software 
No 
Cpnd present, no MS-
MS collected by 
software 
Cpnd at same RT as S1; 
no MS-MS collected by 
software  
Cpnd at same RT as S1; 
no MS-MS collected by 
software 
No 
MS-MS confirmation MS-MS confirmation Present, but at RT > ± 0.3 min from S1 and S2 No 
MS-MS confirmation 
Cpnd at same RT as S1; 
no MS-MS collected by 
software 
Not present in peak list No 
MS-MS confirmation 
Present, but at RT > ± 
0.3 min from S1; MS-
MS confirm? 
Not present in peak list No 
Table 5: Criteria for positive identification of protein adducts following HN-2 and HN-3 incubation 
 
 Each experiment (triplicate of each HN condition plus a control protein) was performed a 
total of four times. The final determination for identification of an adduct would require 
that it be positively identified (as described in the bullet points and table above) in at least 
three of the four independent experiments. An identified adduct must have been present 
in each experiment at the same RT (± 0.3 min), else it would not be considered. 
The HN-2 and HN-3 adducts identified as described below represent findings that met all of the 
above-mentioned criteria for positive adduct identification. Figure 25 depicts the data analysis 
flow utilized for these experiments. The specific parameters in BioConfirm were selected 
utilizing recommendations from the manufacturer and assistance from the software 
familiarization guide. 
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Figure 25: Data processing workflow utilizing BioConfirm and Protein Prospector 
 
4.2.1. Direct Injection Analysis of Full Proteins 
 Initial direct injection experiments were performed in order to determine the minimum 
excess concentration of HN required for an observable shift in both Hb and HSA deconvoluted 
masses. Despite observable mass shifts in the direct injection samples, the only method of 
confirmation was via protein digestion (discussed below). Nevertheless, direct injection analysis 
provided a rapid screening method to determine exposure-response relationships with the full 
proteins. Deconvolution parameters are detailed in Appendix 5. 
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 Direct injection analysis of native Hb yielded two individual protein peaks – one 
representing the alpha (α) subunit with a molecular weight of 15,126 Da, and the second 
representing the beta (β) subunit with a molecular weight of 15,867 Da. Additionally, the MS 
spectral data included a peak representative of the heme group (molecular weight of 616 Da). 
Deconvoluted masses for the native α and β subunits of Hb were consistent over time and 
accurate when compared to theoretical literature values for subunit mass,135,136 demonstrating the 
usefulness of the analysis method and deconvolution parameters. Based on the direct injection 
experiments for Hb incubated with HN-2 and HN-3, a molar excess of 100:1 was deemed 
necessary for further adduction experiments with Hb. 
 Direct injection analysis of HSA yielded results that were less consistent, but expected. 
HSA is a much larger protein (66,473 Da) and as such, produces a more complicated MS 
spectrum for deconvolution purposes. In addition, due to other potential post-translational 
modifications and genetic variability, the molecular weight of HSA will vary. Commercial 
vendors provide an expected range for the deconvoluted mass of HSA that varies up to 200 Da 
higher than the projected mass based on amino acid composition. This variation was taken into 
consideration when analyzing HSA, and unmodified HSA did indeed fit within this window each 
time using the same lot of lyophilized HSA. Based on the direct injection analysis of HSA 
incubated with HN-2 and HN-3, a molar excess of 50:1 HN was deemed necessary for observable 
mass shift as a result of adduction for further digestion experiments. 
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4.2.2. HN-2 Adduction to Hemoglobin 
 After exposure to HN-2, a total of three novel, specific His adducts were positively 
identified. Of these three identified His modifications, two were on the β chain and the third on 
the α chain. In addition, adduction to N-terminal Val residues on both the α and β chain were 
confirmed through these studies. 
 Figure 26 shows a representative MS-MS spectrum for the confirmation of the α-N-
terminal adduction on the tryptic fragment VLSPADKTNVK. While the modification of the N-
terminus has been previously published,94 there has not been MS-MS confirmation of this adduct 
on the reactive site, nor has there been any specification as to which N-terminus (α or β) was 
modified. In the case of HN-2, reproducible modification of both N-termini was observed. 
 
Figure 26: MS-MS identification of Hb α N-terminal adduction by HN-2. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of α (blue) and β (yellow) chains of Hb, with 
adducted residue (α N-term) highlighted in red. (C) Fragmentation diagram for MS-MS data, with 
adducted N-terminal structure. 
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 Figure 27 demonstrates HN-2 adduction to the β-N-terminus on the tryptic fragment 
VHLTPEEK. As previously mentioned, this is the first documented MS-MS confirmation of HN-
2 to this adduction site. 
 
Figure 27: MS-MS identification of Hb β N-terminal adduction by HN-2. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of α (blue) and β (yellow) chains of Hb, with 
adducted residue (β N-term) highlighted in red. (C) Fragmentation diagram for MS-MS data, with 
adducted N-terminal structure. 
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 The three novel protein adducts on Hb for HN-2 were all His modifications. Figure 28 
demonstrates the HN-2 modification of His-50α, the only novel reproducible modification 
observed for the α subunit via the tryptic fragment TYPFHFDLSHGSAQVK. 
 
Figure 28: MS-MS identification of Hb His-50α adduction by HN-2. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of α (blue) and β (yellow) chains of Hb, with 
adducted residue (His-50α) highlighted in red. (C) Fragmentation diagram for MS-MS data, with 
adducted His residue structure. 
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 The other two previously undocumented HN-2 protein His adducts were found on the β 
chain of Hb. The first is His-77β, on the tryptic fragment VLGAFSDGLAHLDNLK. 
Representative MS-MS fragmentation may be seen in Figure 29. 
 
Figure 29: MS-MS identification of Hb His-77β adduction by HN-2. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of α (blue) and β (yellow) chains of Hb, with 
adducted residue (His-77β) highlighted in red. (C) Fragmentation diagram for MS-MS data, with 
adducted His structure. 
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 The final HN-2 adduct is present on His-143β, on the tryptic fragment 
VVAGVANALAHK. Representative MS-MS fragmentation may be seen in Figure 30. 
 
Figure 14: MS-MS identification of Hb His-143β adduction by HN-2. (A) Representative MS-MS 
data of tryptic peptide. (B) Space-filled model of α (blue) and β (yellow) chains of Hb with adducted 
residue (His-143β) highlighted in red. (C) Fragmentation diagram for MS-MS data, with adducted 
His structure. 
 
4.2.3. HN-3 Adduction to Hemoglobin 
 HN-3 adduction to Hb produced novel adducts on the identical His residues as observed 
for HN-2, a result that was expected given previous results obtained from model peptide studies. 
However, only one N-terminal modification by HN-3 was positively identified via the criteria 
listed above. Figure 31 shows the MS-MS fragmentation for HN-3 adduction of the β-N-terminus 
via the tryptic peptide VHLTPEEK. While adduction to the α-N-terminus by HN-3 was observed 
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in some samples, it did not meet the strict criteria set above and was therefore not included in the 
results. 
 
Figure 31: MS-MS identification of Hb β N-terminal adduction by HN-3. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of α (blue) and β (yellow) chains of Hb, with 
adducted residue (β N-term) highlighted in red. (C) Fragmentation diagram for MS-MS data, with 
adducted N-terminal structure. 
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 Figure 32 demonstrates the results of HN-3 adduction to His-50α via the tryptic fragment 
TYPFHFDLSHGSAQVK.  
 
Figure 32: MS-MS identification of Hb His-50α adduction by HN-3. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of α (blue) and β (yellow) chains of Hb, with 
adducted residue (His-50α) highlighted in red. (C) Fragmentation diagram of MS-MS data, with 
adducted His structure. 
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 Figure 33 demonstrates representative results of HN-3 adduction to His-77β via the 
tryptic fragment VLGAFSDGLAHLDNLK.  
 
Figure 33: MS-MS identification of Hb His-77β adduction by HN-3. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of α (blue) and β (yellow) chains of Hb, with 
adducted residue (His-77β) highlighted in red. (C) Fragmentation diagram for MS-MS data, with 
adducted His structure. 
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 Finally, Figure 34 demonstrates adduction of HN-3 to His-143β via the tryptic fragment 
VVAGVANALAHK. 
 
Figure 34: MS-MS identification of Hb His-143β adduction by HN-3. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of α (blue) and β (yellow) chains of Hb, with 
adducted residue (His-143β) highlighted in red. (C) Fragmentation diagram for MS-MS data, with 
adducted His structure. 
 
4.2.4. HN-2 Adduction to Human Serum Albumin 
 Adduction assessment of HSA revealed a total of three novel, specific HN-2 adducts, two 
of which were Lys modifications, and the third a His modification. In addition, since the N-
terminus of a protein is generally considered to be a reactive site (so long as it is not blocked), 
HN-2 was also determined to adduct to the N-terminal Asp residue of HSA. Figure 35 provides 
MS-MS confirmation of N-terminal Asp adduction of HSA by HN-2. 
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Figure 35: MS-MS identification of HSA N-terminal modification by HN-2. (A) Representative MS-
MS spectrum of tryptic peptide. (B) Space-filled model of HSA with adducted residue (N-term) 
highlighted in red. (C) Fragmentation diagram for MS-MS data, with adducted N-terminal 
structure. 
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 Two specific HN-2 adducts were identified on HSA on Lys residues. The first may be 
seen in Figure 36, which demonstrates results obtained from HN-2 adduction to Lys-233 via the 
tryptic peptide AEFAEVSKLYTDLK. 
 
Figure 36: MS-MS identification of HSA Lys-233 adduction by HN-2. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of HSA, with adducted residue (Lys-233) 
highlighted in red. (C) Fragmentation diagram for MS-MS data, with adducted Lys structure. 
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 The second adducted Lys residue is Lys-317, as seen in Figure 37, via the tryptic 
fragment DVCKNYAEAK. The data also demonstrates that Cys-316 present in this peptide has 
been alkylated with iodoacetamide during sample processing. This was expected, as Cys-316 is 
present in HSA as a disulfide and would thus not be adducted by HN-2 via the protocol utilized in 
this experiment. 
 
Figure 37: MS-MS identification of HSA Lys-317 adduction by HN-2. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of HSA, with adducted residue (Lys-317) 
highlighted in red. (C) Fragmentation diagram for MS-MS data, with adducted Lys structure. 
 
  
  
84 
 Finally, the third novel HN-2 protein adduct identified in this work is His-376, via the 
tryptic peptide CCAAADPHECYAK. The three Cys residues present in this peptide have all been 
alkylated by iodoacetamide, which is supported by the MS-MS data seen in Figure 38. As these 
three Cys are naturally in disulfide bonds in the HSA native structure, they also were not 
expected to be adduction sites for HN-2. 
 
Figure 38: MS-MS identification of HSA His-367 adduction by HN-2. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of HSA, with adducted residue (His-367) 
highlighted in red. (C) Fragmentation diagram for MS-MS data, with adducted His structure. 
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4.2.5. HN-3 Adduction to Human Serum Albumin 
 As with HN-2, HN-3 adduction to HSA yielded two novel, specific protein adducts on 
Lys residues. In addition, adduction to the N-terminus was also positively identified. Figure 39 
demonstrates HN-3 adduction to the N-terminal Asp. 
 
Figure 39: MS-MS identification of HSA N-terminus adduction by HN-3. (A) Representative MS-MS 
data of tryptic peptide. (B) Space-filled model of HSA, with adducted residue (N-term) highlighted in 
red. (C) Fragmentation diagram for MS-MS data, with adducted N-terminus structure. 
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 Figure 40 demonstrates HN-3 adduction to Lys-233 via the tryptic peptide 
AEFAEVSKLVTDLK.  
 
Figure 40: MS-MS identification of HSA Lys-233 adduction by HN-3. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of HSA, with adducted residue (Lys-233) 
highlighted in red. (C) Fragmentation diagram for MS-MS data, with adducted Lys structure. 
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 Figure 41 demonstrates HN-3 adduction to Lys-317 via the tryptic peptide 
DVCKNYAEAK. Cys-116 is shown via MS-MS data to be alkylated by iodoacetamide, as was 
seen with HN-2. 
 
Figure 41: MS-MS identification of HSA Lys-317 adduction by HN-3. (A) Representative MS-MS 
spectrum of tryptic peptide. (B) Space-filled model of HSA, with adducted residue (Lys-317) 
highlighted in red. (C) Fragmentation diagram for MS-MS data, with adducted Lys structure. 
 
 Adduction to His-367 by HN-3 was observed in several different samples; however, due 
to the strict criteria set for identification, was not determined to be reproducible for this work.  
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4.2.6. Stability of Full Protein Adducts 
 The stability of the identified adducts was determined over a three-week period. As a 
strict set of criteria had already been employed for initial adduct identification, the requirements 
for MS-MS data in selecting true positives were not as stringent in these experiments. For the 
positive identification of adducts during the stability study, it was only deemed necessary for 
identified adducts to be present at the same RT as previously identified. If MS-MS data were 
available for identified adducts, it was analyzed by comparison to a theoretical peak list generated 
by Protein Prospector. 
 As with previous experiments, triplicate samples were run for each condition. In the 
tables below, a check mark () corresponds to positive identification of the adduct in at least two 
of the three samples. An x () in the table corresponds to the adduct missing in the peak list in 
two or more of the triplicate samples. It is important to note that, for each time point, aliquots 
were removed from the same sample. Therefore, a non-identification at one time point should not 
necessarily be grounds for characterizing an adduct as unstable. These non-identifications may be 
a result of variations with the digestion or the Auto MS-MS analysis. An adduct was therefore 
considered stable if it was present at the three-week time point and was consistently documented 
during the analysis period. 
 Table 6 demonstrates the stability of identified HN-2 adducts over a three-week analysis 
period. All adducts identified were present at the 3 h and 3 week time points, and therefore were 
considered stable during the analysis period. 
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Hemoglobin 
Adduct Site Time Point 3hr 24hr 1wk 2wk 3wk
α N-term      
His-50α      
β N-term      
His-77β      
His-143β      
Human Serum Albumin 
Adduct Site Time Point  3hr 24hr 1wk 2wk 3wk
N-term      
Lys-233      
Lys-317      
His-367      
Table 6: Stability of identified HN-2 adducts to Hb and HSA over three weeks following adduct 
formation. 
 
Results for the stability studies for HSA adducts were more variable than with Hb. However, as 
missing adducts were only noted at a single time point for each adduct, this observation is most 
likely due to variation with the digestion or the Auto MS-MS trigger, rather than instability of the 
adduct. 
 Table 7 demonstrates the stability of identified HN-3 adducts over the three-week 
analysis period. All adducts identified were present at the 3 h and 3 week time points, with 
consistent identification during the analysis period; therefore, these adducts were considered 
stable during the entire analysis period. 
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Hemoglobin 
Adduct Site Time Point 3hr 24hr 1wk 2wk 3wk
His-50α      
β N-term      
His-77β      
His-143β      
Human Serum Albumin 
Adduct Site Time Point  3hr 24hr 1wk 2wk 3wk
N-term      
Lys-233      
Lys-317      
Table 7: Stability of identified HN-3 adducts to Hb and HSA over three weeks following adduct 
formation. 
 
As with Table 6, cells containing an  indicate that the adduct could not be identified in at least 
two of the three samples tested. This phenomenon occurred at a maximum of a single time point 
per adduction site; therefore, the adducts were in all cases considered stable.   
 
4.2.7. Discussion 
 The experiments presented above have identified several novel and specific protein 
adducts for HN-2 and HN-3 on Hb and HSA that are stable over at least a three-week analysis 
period. These modifications therefore have potential as specific biomarkers of exposure for these 
two CWA. All adducts identified in this task were hydroxylated and no longer contained the 
chlorine atom. The fully hydroxylated form of the adduct should therefore be considered the more 
relevant structure for biological proteins and for the metabolic assays. 
 The identified adduction sites for HN-2 show a good overlap with those of HN-3, 
although fewer adducts were confirmed for HN-3. This is not surprising for two reasons. First, 
HN-2 has been documented to be more reactive than its HN-3 counterpart.37 As such, more 
adduction would be expected for HN-2. Second, HN-3 has more potential for steric hindrance in 
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its reactivity than HN-2. It is possible that the larger HN-3 molecule cannot reproducibly adduct 
sites that are less accessible, and therefore appears to be less reactive than HN-2.  
 An additional observation regarding the HN-2 and HN-3 adducts is the location of all the 
adduction sites. All susceptible residues are located on the surface of these proteins, where they 
are largely accessible to electrophilic species. Due to this observation, it was of interest to further 
analyze the surface content of Lys and His residues on the two proteins studied. Figure 42 below 
demonstrates a space-filled model of Hb, with the surface Lys and His residues highlighted in red 
and yellow, respectively. 
 
Figure 42: Space-filled model of Hb, with highlighted Lys (A) and His (B) residues. The alpha chain 
is colored blue, the beta chain is colored yellow, the red resides represent the outer Lys residues, and 
the pink residues represent the outer His residues. 
 
The figure above suggests that there are several outer Lys residues (red); however, only His 
modifications were observed as reproducibly adducted by HN-2 and HN-3. The most likely 
explanation is the lower pKa of His residues at pH 7.4 as compared to Lys residues – despite the 
larger number of surface Lys residues, they are also most likely charged and therefore not idea 
species for adduction. 
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Figure 43 below demonstrates the outer Lys (red) and His (pink) residues for HSA. 
 
Figure 43: Space-filled model of HSA, with Highlighted Lys (A) and His (B) residues. HSA is shown 
in blue, the red residues represent the outer Lys residues, and the pink residues represent outer His 
residues. 
 
Immediately evident by this figure is the larger number of Lys residues (red) present on the 
surface of HSA, when compared to surface His residues (pink). Unlike Hb, adduction of HN-2 
and HN-3 at two Lys residues was identified reproducibly. This suggests that, despite the higher 
base pKa value of Lys, local electronic factors within HSA may allow for these sites to be 
adducted by HN-2 and HN-3. Additional work should be performed in which the local electronic 
environment for these sites are analyzed further (particularly for the Lys residues on HSA) for 
theoretical explanation of site specific modification by HN-2 and HN-3.   
 The focus of this research was to identify novel and specific adduction sites of HN-2 and 
HN-3 to Lys and His residues as additional exposure biomarkers that may be more applicable 
than those previously identified for these compounds. This was indeed accomplished with the 
identification of reproducible Lys and His adduction by both HN-2 and HN-3. However, the 
results obtained for this task did not reveal specific modification of the known reactive Cys 
residues on Hb (Cys-93β) or HSA (Cys-34). Several hypotheses can be proposed to account for 
why such adducts were not identified in the present study. 
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 For Hb (Cys-93β), no formal identification of HN-2 or HN-3 modification has been 
published. This residue is considered highly reactive due to its proximity to His-92β, which is 
partially responsible for heme incorporation into the Hb tertiary structure,55 therefore affecting the 
Cys local environment so that it is more susceptible for adduction (more nucleophilic). However, 
this residue is also present in a hydrophobic pocket of the protein, which would be difficult for a 
hydrophilic or charged intermediate (such as reactive HN-2 and HN-3 aziridinium intermediates) 
to access. This possibility is, in part, supported by the data obtained in the present task, where all 
identified HN-2 and HN-3 modifications were localized on the surface of the protein. In addition, 
HN-2 and HN-3 are known to hydrolyze quickly in aqueous environment – as such, it may be that 
these reactive species would not be present long enough to adduct to Cys-93β, in view of its low 
accessibility.  
 For HSA (Cys-34), it was expected that this residue would be modified by HN-2 and HN-
3, based on work from previous researchers.93,133 However, it is important to compare the 
methodologies utilized in these publications to those employed in the present study. Noort et al. 
identified HN-2 Cys-34 adducts following Pronase digestion of HSA based on previous work 
done with identification of Cys-34 adducts by sulfur mustard.80 Pronase is a proteolytic enzyme 
that is relatively non-specific in terms of protein cleavage.100 A second method utilized in that 
work was HCl digestion, a technique used to break a protein into many small peptides. Both of 
these approaches are quite useful in producing small, manageable peptides for analysis; however, 
they are not optimal when trying to identify novel sites of adduction (as was the goal of this 
work). For such an application, a proteolytic enzyme is needed that has a high level of specificity 
so as to easily predict peptides formed from a protein digest, which can then be used for 
prediction of adduction sites. Trypsin was intentionally utilized for this project for its specificity; 
however, the tryptic fragment produced containing the Cys-34 residue is a large-mass peptide (21 
amino acids) that may be lost or difficult to detect.  
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 In addition, Noort and colleagues were able to detect the HD Cys modification by means 
of radiolabeled sulfur mustard and isolation of an LC fraction, later identified as a Cys-modified 
tri-peptide. This result was further confirmed through comparison to a synthetic standard once the 
tri-peptide was characterized. Identification of the HN Cys-34 adduct was assumed to occur on 
the same tri-peptide following pronase digestion, which was indeed the case. Consequently, the 
sensitivity for detection of the Cys-34 specific modification was likely to be higher in the 
previous work than in the present study. 
 Finally, because of the variety of amino acids present on the expected tryptic fragment 
containing Cys-34, it is possible that multiple residues within the peptide may have been 
modified, or that HN-2/HN-3 may be forming cross-links on the peptide. The expected tryptic 
fragment containing Cys-34 on HSA is ALVLIAFAQYLQQCPFEDHVK. While the Cys is an 
expected adduction site, the His may also be available for adduction, in addition to other 
nucleophilic residues such as Tyr (T), Glu (E), and Asp (D). While a His residue would be 
allowed in the BioConfirm Data analysis, a third adduction to Tyr, Glu, or Asp would cause the 
peptide to be missed by BioConfirm using the parameters listed in Appendix 5 (potential 
adduction by HN-2/HN-3 to other amino acids is further discussed in Section 4.5). Furthermore, 
if a cross-link exists between any of these sites, this modification would also not have been 
determined and therefore not programmed into BioConfirm to recognize. Recent work regarding 
nitrogen mustards has identified their ability to cross-link in proteins;137 it is possible that, given 
the surrounding amino acids, a cross-link exists that is currently unknown. Further work, 
including confirmation of adduction to additional amino acids, further optimization of LC-MS-
MS parameters, and investigation of HN-2 and HN-3 crosslinking, would therefore be required to 
identify the Cys adduct given the conditions used for this work. 
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4.3. Whole Blood Incubation and In Vitro Protein Adduction 
 Finally, a proof-of-concept study was performed in which whole blood was incubated 
with HN-2 and HN-3 to determine whether the identified Hb and HSA adducts would form in a 
simulated in vivo environment. Prior to HN incubations, the precipitation extraction procedures 
for Hb and HSA were tested via C8 analysis for general determination of extraction purity. Figure 
44 compares the Hb extracted from whole blood to a standard created from lyophilized protein 
purchased at high purity.  
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Figure 44: C8 reversed phase LC analysis of extracted Hb (green) as compared to a standard protein 
(red). A: TIC; B: Deconvolution results for the control α and β peaks; C: deconvolution results for 
extracted α and β peaks, demonstrating successful extraction and identification of Hb from whole 
blood. 
 
 The extraction method for Hb provided a clean extraction and was therefore considered 
acceptable for the whole blood incubation studies. The slight variation in RT between extracted 
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and purified proteins was within the previously set cutoff of ± 0.3 min and therefore considered 
acceptable. Additionally, the split peak observed for the β subunit is most likely a variant as a 
results of Hb extraction from a pooled blood sample. 
 Figure 45 compares the HSA extracted from whole blood to a standard created using 
lyophilized HSA purchased at high purity. As with Hb, the HSA precipitation extraction provided 
clean results that were deemed acceptable for this work. As mentioned previously for Hb, the 
deconvoluted mass difference is most likely a result of variability (genetic or otherwise) between 
the pure standard and the extracted blood sample, in addition to the complexity of MS data 
obtained for deconvolution. 
 
Figure 45: C8 reversed phase LC analysis of extracted HSA (green) as compared to a protein 
standard (red). A: TIC; B: Deconvolution results for HSA standard; C: Deconvolution results for 
extracted HSA, showing successful identification and extraction of HSA from whole blood. 
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 There are several different methods in which proteins may be extracted from whole 
blood. The precipitation reactions selected for this work were chosen due to their use in previous 
adduct studies; however, newer methods have been introduced that may also provide acceptable 
recoveries for the proteins of interest. Affinity chromatography has been increasingly utilized for 
the extraction of HSA from serum, with excellent results.138 During initial determinations of 
extraction methods suitable for this work, affinity columns were tested for the extraction of 
adducted HSA, and demonstrated similar results as seen with the precipitation extraction of HSA. 
The precipitation reaction was ultimately chosen as the method of choice due to its use of fewer 
reagents, cost-effectiveness, and time-saving protocol. While the results obtained for this 
particular experiment were comparable between the two protocols, it is possible that other 
adduction studies may produce adduct structures that may hinder the recognition of HSA in the 
affinity column due to the modification. Care should therefore be taken when extracting modified 
HSA in such cases. 
 Whole blood was incubated with HN-2 and HN-3 and the HSA was separated from the 
plasma, while the Hb was separated from the erythrocytes. Extracted proteins were then digested 
and analyzed via LC-Q-TOF-MS-MS. Analysis of triplicate blood samples for HN-2 and HN-3 
revealed the presence of the previously identified specific adducts, matched by modification 
description and retention time. These in vitro incubations demonstrate the stability of the adducts 
even after precipitation extraction of Hb and HSA, which further strengthens their potential use as 
exposure biomarkers to HN-2 and HN-3. 
 Additional validation of Hb and HSA adducts identified in this study as potential specific 
biomarkers of HN exposure would benefit from in vivo studies in animal models.  However, care 
must be taken in extrapolating the results of adduction studies in animal models to predict 
specificity in humans. Typically, toxicity studies are done using a rat model.139 However, despite 
the large overlap between human and rat Hb and serum albumin (SA) sequences, some of the 
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adduction sites identified in the present study do not exist in rat Hb or SA. Figure 46 shows a 
comparison between the α and β chains of Hb in human and rat. Adduction to His-50α could not 
occur in rat Hb, as this site is not conserved (His-50α is replaced with a Pro at this site). 
 
Figure 46: Comparison of the Hb amino acid sequences of human and rat. Sites highlighted in green 
are conserved within species, while the sites highlighted in red are not conserved between species. 
 
 Figure 47 shows a comparison of the SA sequences for human and rat. While both Lys 
residues of interest are conserved in the rat, the N-terminus is a Glu (versus Asp) in rat. 
Additionally, His-367 is replaced with a Pro. 
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Figure 47: Comparison of SA amino acid sequences of human and rat. Sites highlighted in green are 
conserved among species, whereas sites highlighted in red are not conserved between species. 
 
 These differences emphasize the importance in using human proteins for the development 
of specific adduct-based exposure biomarkers for this class of compounds. 
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4.4. In Vitro Metabolism of Nitrogen Mustard Therapeutic Compounds 
 The previously obtained results provided a strong indication that the hydrolyzed adducts 
(HN-2 OH and HN-3 OH) were the more relevant adducts in terms of biological protein 
adductions and long-term exposure biomarkers; therefore, for the metabolic studies, it was of 
interest to determine whether commonly encountered therapeutic drugs containing the nitrogen 
mustard moiety (cyclophosphamide, chlorambucil, and melphalan) would, after metabolism, 
produce the same covalently bound adducts as HN-2 or HN-3. The structures of these compounds 
may be seen in Figure 48. As the goal of this project is to identify not only novel, but specific 
biomarkers of exposure, it is of high importance to assess whether these drugs are also capable of 
forming the same adducts on Cys, Lys, or His. 
 
Figure 48: Structures of commonly used nitrogen-mustard containing therapeutic agents studied in 
the present investigation. 
 
 As detailed in the methods section, a SIM method was utilized for this experiment. While 
it is known that these therapeutic compounds are capable of adducting to nitrogen in DNA (as this 
is their mode of action as antineoplastic drugs),24,46,114 the focus here is to ensure that protein 
adduction by these drugs would not produce the same adduct structures as previously identified 
for HN-2 and HN-3. Therefore, SIM methods were utilized as a rapid comparison for adducts of 
interest, as the molecular weights and RT of HN-adducted peptides were identified and 
characterized in previous studies. In addition, controls were utilized in which HN-2 and HN-3 
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were added to the metabolic systems. It was been shown in the present and previous work that 
these compounds will adduct to model peptides without the need for metabolic assays; therefore, 
it would be reasonable to expect that previously identified adducts would still be generated in 
these control assays. 
 
4.4.1. Cyclophosphamide 
 The previously reported metabolic pathway of CP may be found in Appendix 1. The 
reactive species formed after metabolism is nornitrogen mustard, which contains the same 2-
chloroethyl backbone as HN-2 and HN-3; however, the third group on the central nitrogen is a 
hydrogen vs. a methyl (HN-2) or 2-chloroethyl (HN-3). As such, it is not expected that 
metabolized CP will form the same adduction species with the model peptides as is seen with 
HN-2 or HN-3. 
 MS analysis of the control samples metabolized by S9 fraction demonstrated expected 
peaks corresponding to previously identified hydroxylated adducts. These adducts were 
confirmed via full-scan MS analysis of the assay samples and RT matching from previously run 
samples. When the control samples were compared to the respective SIM trace obtained in 
triplicate CP samples, there were no overlapping peaks present, meaning that S9-metabolized CP 
does not produce the same hydroxyl adducts with  Cys, Lys, or His as HN-2 or HN-3. 
Representative results of S9-metabolized CP and corresponding control experiments may be seen 
in Figure 49. 
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Figure 49: S9-metabolism of CP, as compared to controls (peptides incubated with HN-2 and HN-3) 
samples. HN-2 (a-c) and HN-3 (d-f) controls were present in respective samples, but no overlap was 
seen with CP-containing triplicates [black lines]. 
 
 HLM-metabolized CP samples yielded similar results to the S9-metabolized samples. All 
control samples yielded peaks corresponding to previously identified hydroxyl adducts of HN-2 
and HN-3 with the model peptides, confirmed via full scan MS analysis and RT matching. When 
compared to CP-containing samples, no overlap was observed at the same RT as the control 
samples. Based on these results, HLM-metabolized CP does not produce the same adducts with 
Cys, Lys, and His as HN-2 or HN-3 (Figure 50). 
104 
 
Figure 50: HLM-metabolized CP [black trace] as compared to HN-2 (a-c) and HN-3 (d-f) controls. 
 
4.4.2. Chlorambucil 
 The previously documented metabolism for CB may be found in Appendix 2. The 
primary metabolite of CB is phenylacetic acid mustard, formed via β-oxidation of the parent 
compound. No known metabolites of CB have been determined in which the phenylacetic acid 
group is not attached. 
 Analysis of the control samples after S9 metabolism yielded similar results as seen with 
cyclophosphamide. SIM peaks corresponding to the HN-2 and HN-3 hydroxylated adducts were 
correctly identified based on full scan MS analysis and RT matching from previously run 
samples. When compared to CB-containing samples, there were no peaks that matched to the 
control samples (Figure 51). Therefore, based on these results, S9-metabolized CB does not form 
the same hydroxylated adducts as HN-2 or HN-3.   
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Figure 51: S9 metabolized CB [black trace] as compared to control samples HN-2 (a-c) and HN-3 (d-
f). 
  
 Analysis of the HLM-metabolized samples yielded similar results as seen with S9 
metabolism. Peaks corresponding to the expected HN-2 and HN-3 hydroxylated adducts were 
present in the control samples, confirmed through full scan MS analysis of the controls and RT 
matching. For all three peptides, there was no overlap observed in the CB-containing samples as 
compared to the controls (Figure 52). These results suggest that, when metabolized with HLM, 
CB does not produce the same adducts as HN-2 or HN-3 with Cys, Lys, or His. 
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Figure 52: HLM metabolized CB [black trace] as compared to control samples HN-2 (a-c) and HN-3 
(d-f). 
 
4.4.3. Melphalan 
 The known metabolic pathway of MP can be found in Appendix 3. The major known 
metabolite for MP is hydroxy-MP; no know metabolites of MP have been identified that do not 
include the benzyl side chain. 
 Controls for the S9-metabolized samples yielded expected peaks corresponding to the 
hydroxylated HN-2 and HN-3 adducts. As with previous controls, these were confirmed via full 
scan analysis of the metabolism samples and RT matching from previous results. When samples 
containing MP were compared to these controls, there were no observed overlaps for the adduct 
peaks. These results demonstrate that S9-metabolized MP will not produce the same adducts as 
HN-2 or HN-3 with Cys, Lys, or His residues (Figure 53). 
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Figure 53: S9 metabolized MP [black trace] as compared to control samples HN-2 (a-c) and HN-3 (d-
f). 
 
 The results obtained from HLM-metabolized samples are similar to what was obtained in 
the S9 fraction. Control samples yielded expected SIM peaks corresponding to hydroxylated HN-
2 and HN-3 adducts, confirmed through full scan analysis of the metabolized samples and RT 
matching from previous results. Metabolized samples containing MP were compared to these 
control samples, and no overlap was observed in all six conditions. Based on these results, HLM-
metabolized MP will not form the same adducts as HN-2 or HN-3 with Cys, Lys, or His (Figure 
54). 
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Figure 54: HLM metabolized MP [black trace] as compared to control samples HN-2 (a-c) and HN-3 
(d-f). 
 
4.4.4. Discussion 
 It is of importance to note that this study was not intended to characterize specific 
adducts formed by reactive species present after metabolism of these drugs (nornitrogen mustard, 
etc.). In fact, based on the known reactivity of nitrogen mustards in general, it is likely that such 
reactive metabolites did form adducts with the nucleophilic residues present on these peptides. 
However, the metabolic assays conducted under this task successfully demonstrated that, despite 
some structural similarities to the CWA HN-2 and HN-3, the three therapeutic drugs tested 
(Cyclophosphamide, Chlorambucil, and Melphalan) did not produce the same specific adduct 
structures as observed for HN-2 or HN-3 at each of the three nucleophilic sites of interest. This is 
an important set of results, as it indicates that prior or concurrent exposure to such drugs would 
not result in false positive detection of HN exposure based on specific adduct detection. 
Nevertheless, it is possible that such drugs could adduct the same sites on Hb and HSA as HN-2 
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and HN-3 to produce structurally distinct adducts.  This possibility could be evaluated in future 
research.  
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4.5. Quantum Mechanical Calculations 
4.5.1. Electrophilicity of Nitrogen Mustards and Related Intermediates 
 Table 8 shows the calculated chemical potentials (μ) and hardness values (η) (as 
calculated from Equations 2 and 3) for HN-2 and its related intermediates based on the HOMO-
LUMO energies obtained from Gaussian. The compounds are listed in order from most 
electrophilic (more negative chemical potential) to least electrophilic. In addition, the table also 
includes data for a comparative compound, acrylamide, which is a known neurotoxicant and has 
previously been classified as a soft electrophile,62 for comparison purposes to the obtained HN-2 
data. 
Compound Name Structure μ (eV) η (eV) 
HN-2 Az Cl N+
Cl
-7.97 3.95 
HN-2 Az OH N+
OH
-7.34 4.12 
HN-2 N
ClCl
-2.97 3.42 
HN-2 OH Cl N
ClOH
-2.67 3.41 
HN-2 OH OH N
OHOH
-1.90 3.83 
Acrylamide 
NH2
O
-3.80 2.96 
Table 8: Calculated chemical potentials (μ) and hardness values (η) for HN-2 and related 
intermediates, as calculated by Equations (2) and (1), respectively. Acrylamide is used as a reference 
compound for comparison purposes. 
 
These results demonstrated that the Az ion containing one chlorine still attached is the 
most electrophilic species of the HN-2 intermediates, and therefore most likely to bind to 
nucleophilic species as compared to other HN-2 intermediates. This adduct may then undergo 
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hydrolysis in aqueous environments to yield the stable hydroxylated adducts observed in this 
work. It is also important to note that the hydroxylated Az is also a strong electrophile, as shown 
in Table 8. Adduction may therefore follow a secondary path in which the HN-2 Az Cl 
intermediate first hydrolyzes, followed by adduction. Current research is still unclear as to which 
mechanism occurs in aqueous conditions, or whether both mechanisms occur simultaneously. 
Regardless, these calculations not only support previous hypotheses regarding the formation of 
these Az ions as the electrophilic species responsible for protein and DNA binding, they also 
suggest that multiple pathways are possible as both Az species are comparably electrophilic. The 
final compound formed from HN-2 hydrolysis (HN-2 OH OH, or N-methyldiethanolamine) was 
determined to have the highest value for chemical potential, and therefore the least nucleophilic 
character of the HN-2 intermediates. This finding is supported in experimental data, in which 
model peptides incubated with HN-2 OH OH for 24 h at physiological conditions did not yield 
adducts on Cys, Lys, or His. 
In terms of chemical hardness calculations (calculated via Equation 1), the larger the 
value of η, the “harder” the compound is expected to be. Hard electrophiles are typically 
described as containing a localized charge density around a central electrophilic center.62 In the 
case of nitrogen mustards, the positively charged nitrogen in the center of the molecule would 
house the charge density for the molecule. The calculated hardness values for HN-2 and its 
intermediates indicate that these compounds may be considered as hard electrophiles. While there 
is no distinct cutoff in hardness values that can be used to distinguish between hard and soft 
compounds, the calculated values for compounds typically considered to be soft may be used as 
relative comparisons. As previously mentioned, acrylamide is a selective neurotoxicant that has 
been described as a soft electrophilic species. The hardness values for the calculated HN-2 
intermediates are higher than that of acrylamide, again suggesting that these compounds should 
be classified as hard or moderately hard electrophilic species. As a consequence, their reactivity 
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towards nucleophilic species should be expected to occur not only on soft nucleophiles such as 
thiol, but on other harder species such as Lys and His. 
Table 9 demonstrates the chemical potential values (µ) and hardness values (η) for HN-3 
and its related intermediates, as calculated by Equations 1 and 2. As with HN-2, acrylamide is 
listed at the bottom of the table as comparison. Compounds are ranked by the most negative 
chemical potential (most electrophilic species) to those with the least negative chemical potential 
(least electrophilic species). 
 As with HN-2, the HN-3 Az species demonstrate the most negative chemical potential 
values, and therefore are considered the most electrophilic species. This again lends credibility to 
the hypothesized formation of the Az ion being the intermediate that binds to nucleophilic species 
such as proteins and DNA. The similarities seen with the chemical potential of these three Az 
species also suggest that a variety of mechanisms are available for adduction. While the double-
chlorinated adduct would be considered the most electrophilic species, the bulk of two chlorines 
present on the molecule may prevent adduction in the case of a steric-hindered nucleophile. For 
this reason, the hydrolyzed species (whether with a loss of one chlorine or both) may be a more 
favored adducting species as they are less bulky and similarly reactive. As with HN-2, the 
terminal intermediate of HN-3 in which all three chlorines have undergone hydroxylation (HN-3 
OH OH OH, or triethanolamine) is the compound with the lowest chemical potential, and 
therefore the intermediate least likely to bind to nucleophilic sites. This is also supported by 
experimental data in which adducts to Cys, Lys, and His did not form at physiological conditions 
when incubated with triethanolamine.  
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Compound Structure µ (eV) η (eV) 
HN-3 Az Cl Cl 
N
+
Cl
Cl -8.09 3.79 
HN-3 Az OH Cl 
N
+
OH
Cl -7.69 3.78 
HN-3 Az OH OH 
N
+
OH
OH -7.31 4.00 
HN-3 N
Cl
Cl
Cl
-3.33 3.37 
HN-3 OH Cl Cl N
OH
Cl
Cl
-3.01 3.38 
HN-3 OH OH Cl N
OH
OH
Cl
-2.72 3.43 
HN-3 OH OH OH N
OH
OH
OH
-2.10 3.75 
Acrylamide NH2
O
-3.80 2.96 
Table 9: Calculated chemical potentials (µ) and hardness values (η) for HN-3 and related 
intermediates, as calculated by Equations (2) and (1), respectively. Acrylamide is included in the 
table for comparison purposes. 
 
 When the hardness values for HN-3 intermediates are compared to a soft electrophile 
(acrylamide), it is evident that these compounds are harder electrophiles. This may explain why 
HN-3 binds not only to the soft thiol on Cys, but also the moderately hard nucleophilic centers of 
Lys and His. The hardness values of HN-2 and HN-3 (and corresponding intermediates) may also 
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be compared with each other. The values for the Az species are all comparable, suggesting that 
HN-2 and HN-3 should interact with a similar set of nucleophiles, a prediction supported by the 
results obtained for both peptide and protein adduction studies. The slight differences in 
adduction between HN-2 and HN-3 may not necessarily be electronically determined, as 
suggested by the similar chemical potential values obtained for HN-2 and HN-3 Az intermediates, 
but instead based on steric limitations of HN-3 over HN-2 as previously proposed. 
4.5.2. Nucleophilicity of Amino Acids 
 Table 10 shows the calculated chemical potential and hardness values for the three amino 
acids that were the focus of this work (Cys, Lys, and His). Values were calculated for both for the 
neutral and deprotonated amino acids. Compounds are ranked from highest chemical potential 
(and therefore the better nucleophile) to lowest chemical potential. As expected, the cysteine 
thiolate is calculated to be the most nucleophilic species studied.  In addition, the calculated 
chemical potential values for neutral Lys and His are very similar. It is also important to note that 
the hardness values of Lys and His are higher than the value for Cys, albeit not extremely so. This 
supports the classification of these two amino acids as “moderately hard” nucleophiles. This 
intermediate value supports the idea that while Lys and His contain nitrogen as the nucleophilic 
atom, they may be susceptible to attack by both soft and hard electrophiles.  
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Amino Acid Charge Structure µ (eV) η (eV) 
Cysteine -1 
O
NH2
S
-
OH 2.18 2.11 
Lysine 0 
O
NH2
NH2 OH -3.08 3.18 
Histidine 0 
O
NH2
N
N
H
OH -3.13 2.74 
Cysteine 0 
O
NH2
SH OH -3.59 3.43 
Lysine 1 
O
NH2
NH3
+
OH -6.78 2.20 
Histidine 1 
O
NH2
N
N
H2
+
OH -7.63 2.49 
Table 10: Calculated chemical potentials and hardness values for amino acids studied in this work, as 
calculated by Equations (2) and (1) respectively. 
 
 Table 11 lists the calculated chemical potential and hardness values for other endogenous 
amino acids not studied in this work, but that may be considered potential alternative binding 
sites for electrophiles. As with Table 10, amino acids are ranked from highest chemical potential 
(better nucleophile) to lowest chemical potential. The values for Cys, Lys, and His are listed in 
red text so as to compare the amino acids to what was studied in this work. 
 As demonstrated by the results, there are several amino acids that have chemical potential 
values which suggest their utility as nucleophilic residues. However, these results should be 
approached with caution, as the pKa values of these residues are an important factor to consider. 
For example, Asp and Glu have pKa values of 4.0 and 4.5, respectively.57 Therefore, at 
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physiological pH (7.4), the majority of these residues will be ionized (-1) and therefore good 
nucleophilic targets. However, Ser and Threonine (Thr) both have higher pKa values, which 
means that at physiological pH, a low percentage of these residues will be ionized. As mentioned 
previously, there are steric and electronic factors within proteins that may produce residues at 
which the local pKa is lowered. Therefore, the above mentioned amino acids may be additional 
nucleophilic sites of interest for HN-2 and HN-3 adduction. It is also important to consider the 
amino acids which may not be charged, but may still have nucleophilic qualities possible for 
adduction. As noted in the table above, there are a few amino acids (Tryptophan, Tyrosine, and 
Arginine) that have chemical potential values high than neutral Lys and His, which have been 
demonstrated in this work to bind to HN-2 and HN-3. Consequently, these residues may also be 
potential nucleophilic targets for future study. 
 
Amino Acid Charge Structure µ (eV) η (eV) 
Serine -1 
O
NH2
O
- OH 2.49 2.19 
Threonine -1 
O
NH2
O
-
OH 2.36 2.23 
Cysteine -1 
O
NH2
S
-
OH 2.18 2.11 
Aspartic Acid -1 OH
O
-
NH2O
O
1.45 2.22 
Glutamic Acid -1 
O O
OHO
-
NH2
1.34 1.74 
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Tryptophan 0 
O
NH2NH
OH -2.77 2.64 
Tyrosine 0 
O
NH2OH
OH -2.84 2.88 
Arginine 0 NH
O
NH
NH2
NH2
OH -3.01 3.03 
Lysine 0 
O
NH2
NH2 OH -3.08 3.18 
Histidine 0 
O
NH2
N
N
H
OH -3.13 2.74 
Asparagine 0 
O
O
NH2
NH2
OH -3.15 3.41 
Threonine 0 
O
NH2
OH
OH -3.18 3.26 
Glutamine 0 
O
O
NH2
NH2
OH -3.19 3.33 
Serine 0 
O
NH2
OH OH -3.20 3.28 
Glutamic Acid 0 
O O
OHOH
NH2
-3.38 3.38 
Aspartic Acid 0 OH
OH
NH2O
O
-3.46 3.27 
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Cysteine 0 
O
NH2
SH OH -3.59 3.43 
Arginine 1 NH
O
NH
NH3
+
NH2
OH -6.61 2.38 
Lysine 1 
O
NH2
NH3
+
OH -6.78 2.20 
Histidine 1 
O
NH2
N
N
H2
+
OH -7.63 2.49 
Table 11: Calculated chemical potential and hardness for ionizable endogenous amino acids, as 
calculated by Equations (2) and (1) respectively. 
  
4.5.3. Estimation of Nucleophile-Electrophile Interaction 
 While chemical potential and hardness values provide some support for predictive 
aspects of electrophilic adduction to biological nucleophiles, a better indicator is the Reactivity 
Index (ω-), as calculated via Equation 3. This value uses both calculated chemical potentials and 
hardness values to estimate how well a particular electrophile would react to a specific 
nucleophile. This parameter is important, as both chemical potential and hardness are factors in 
adduction. Table 12 demonstrates the reactivity index for the three amino acids studied in this 
work in conjunction with HN-2 Az Cl as the electrophile (reactivity index calculations for the 
HN-2 Az OH intermediate may be found in Appendix 9). 
Electrophile: HN-2 Az Cl 
Amino Acid (Charge) ω- (eV)
Cysteine (-1) 2.95 
Lysine (0) 0.75 
Histidine (0) 0.71 
Table 12: Calculated reactivity indices for HN-2 Az Cl to nucleophilic amino acids studied in this 
work, as calculated by Equation (3). 
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 As seen with previous results, HN-2 Az Cl is calculated to react more readily with Cys 
than with Lys and His – these results are supported by experimental data observed from the 
peptide relative adduction kinetics study. Since it has been demonstrated in this work that HN-2 
can also adduct to Lys and His, these calculated data can be used to provide a comparison for 
amino acids not directly studied in this work. Table 13 demonstrates the calculated reactivity 
index for other endogenous amino acids with HN-2 Az Cl. The data for Cys, Lys, and His are 
highlighted in red for comparison purposes. 
Electrophile: HN-2 Az Cl 
Amino Acid (Charge) ω- (eV)
Serine (-1) 3.17 
Threonine (-1) 3.11 
Cysteine (-1) 2.95 
Aspartic Acid (-1) 2.58 
Glutamic Acid (-1) 2.32 
Tryptophan (0) 0.82 
Tyrosine (0) 0.81 
Arginine (0) 0.76 
Lysine (0) 0.75 
Asparagine (0) 0.73 
Threonine (0) 0.72 
Glutamine (0) 0.72 
Histidine (0) 0.71 
Serine (0) 0.71 
Glutamic Acid (0) 0.66 
Aspartic Acid (0) 0.64 
Cysteine (0) 0.60 
Arginine (+1) 0.05 
Lysine (+1) 0.04 
Histidine (+1) 0.003 
Table 13: Calculated reactivity index for HN-2 Az Cl for ionizable amino acids as calculated by 
Equation (3). 
 
 The table suggests that, given the right conditions, HN-2 could bind to other amino acids 
besides Cys, Lys, and His. As mentioned earlier, Ser and Thr appear to be appropriate choices for 
future studies, as their neutral forms have reactivity indexes similar to that of Lys and His. 
Additionally, reactivity index data for Tyr and Tryptophan (Trp) indicate potential vulnerability 
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as additional binding sites for HN, as these are known targets for electrophilic adduction by other 
xenobiotics.55  
 Table 14 demonstrates the reactivity index data for HN-3 Az Cl Cl for the amino acids 
studied in this work (calculated data for the other HN-3 intermediates may be found in Appendix 
9). Nucleophiles are ranked from highest to lowest calculated reactivity index value. 
Electrophile: HN-3 Az Cl Cl 
Amino Acid (Charge) ω- (eV)
Cysteine (-1) 3.19 
Lysine (0) 0.82 
Histidine (0) 0.79 
Table 14: Calculated reactivity index values for HN-3 Az Cl Cl to nucleophilic amino acids studied in 
this work, as calculated by Equation (3). 
 
 As demonstrated previously, HN-3 Az Cl Cl is expected to more readily react with Cys 
thiolate than with Lys or His. These values can be used as comparison for other amino acids not 
tested in this work, as can be seen in Table 15. The values for Cys, Lys, and His are highlighted 
in red. 
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Electrophile: HN-3 Az Cl Cl 
Amino Acid (Charge) ω- (eV)
Serine (-1) 3.43 
Threonine (-1) 3.36 
Cysteine (-1) 3.19 
Aspartic Acid (-1) 2.80 
Glutamic Acid (-1) 2.53 
Tryptophan (0) 0.90 
Tyrosine (0) 0.89 
Arginine (0) 0.84 
Lysine (0) 0.82 
Asparagine (0) 0.80 
Threonine (0) 0.79 
Histidine (0) 0.79 
Glutamine (0) 0.79 
Serine (0) 0.79 
Glutamic Acid (0) 0.73 
Aspartic Acid (0) 0.70 
Cysteine (0) 0.67 
Arginine (+1) 0.07 
Lysine (+1) 0.05 
Histidine (+1) 0.007 
Table 15: Calculated Reactivity Index values for HN-3 Az Cl Cl and ionizable amino acids, as 
calculated by Equation (3). 
 
 As with HN-2, the results from HN-3 suggest that there may be other amino acids that 
could be adduction targets for HN-3 and that merit future study.  
4.5.4. Discussion 
 The calculation of reactivity indices discussed above serves a dual purpose. First, the 
chemical potential data obtained for HN-2, HN-3, and respective electrophilic intermediates lends 
additional support for the hypothesis regarding Az binding of proteins and DNA. In addition, the 
calculated hardness values obtained for these electrophilic species, as compared to a known soft 
electrophile, demonstrate that these compound exhibit characteristics of harder electrophiles, 
meaning that they have the potential for adducting a variety of nucleophilic centers. In addition, 
the calculated hardness values for uncharged Lys and His are comparable, suggesting that they 
would react similarly with electrophiles. Again, this is supported by the model peptide work in 
which the extent of adduction by HN-2 and HN-3 to these sites was similar. 
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 Based on the calculated data, the Cys thiolate appears to be the nucleophile most likely to 
react with electrophilic HN-2 and HN-3 Az species. This is supported by the model peptide 
experiments, in which the rate of formation of Cys adducts was greater than for Lys and His. 
 Second, the calculated reactivity data suggests additional amino acids that may be 
potential adduction sites for HN-2 and HN-3 besides the three studied in this work. However, 
along with these predictions, it is important to consider how these amino acids are presented 
under biological conditions, specifically in terms of pKa and ionization. The pKa of a particular 
amino acid will determine whether the side chain is charged or neutral, and at what general 
percentage it would be expected to be in this charged or neutral state. This factor is important 
when considering, for example, the results calculated for Lys and His. The pKa of Lys is 10.4, 
whereas the pKa of His is 6.4.57  This means that, at pH 7.4, virtually no (0.1%) Lys residues will 
be unionized, whereas 90% of His residues are unionized. Therefore, despite the fact that 
calculated reactivity values for these two residues are relatively comparable, it would be expected 
that, all other factors being equal, a greater fraction of His residues would be adducted as 
compared to Lys. This lends support to the obtained experimental data, in which the majority of 
adducted residues determined on full proteins were His. However, as discussed previously, 
electronic and steric factors surrounding individual amino acids may provide a local pKa for a 
specific residue lower than expected, which could render a more favorable adduction site. This 
may be the case for the specific Lys residues adducted on HSA identified in this study. Further 
work would be required to determine the local pKa of these Lys residues based on the amino acids 
surrounding the adduction site.   
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5. SUMMARY AND PROSPECT 
The goal of this project was to identify novel and specific potential exposure biomarkers 
for the chemical warfare agents HN-2 and HN-3 based on adduct formation on the blood proteins 
Hb and HSA. This work has identified and characterized four previously unknown adduction sites 
on Hb and an additional four sites on HSA, all involving Lys and His modification. Adducts 
formed by HN-2 and HN-3 at these specific sites were determined to be stable during a three-
week analysis period and were confirmed in a proof-of-concept study involving in vitro exposure 
of these agents to human whole blood. Characterized adducts were specific to HN-2 or HN-3, and 
were not observed with three common nitrogen mustard therapeutic agents following in vitro 
metabolism. This work also demonstrated, using theoretical quantum mechanical calculations, 
that other additional amino acid residues may provide additional sites of adduction for the 
nitrogen mustard CWA. This work represents a crucial step in the development of useful, longer-
term exposure biomarkers for this class of forensically relevant compounds. 
 The identification of novel exposure biomarkers for HN-2 and HN-3 has great potential 
for forensic analysis. The adducts identified here have the ability to extend the window of 
detection of these compounds as compared to shorter lived ethanolamine metabolites, as 
demonstrated by the stability assessment of these adducts both on model peptides and full 
proteins. In addition, these protein adducts allow for a level of specificity for HN exposure that is 
not available with the ethanolamine metabolites. Once validated, these biomarkers could be 
utilized for testing individuals poisoned with nitrogen mustard CWA, or, perhaps more 
importantly, to identify subjects seeking to manufacture and disperse such materials in terrorist 
attacks.  Finally, these markers could provide definitive evidence of HN CWA exposure distinct 
from other nitrogen mustard containing compounds, including therapeutic compounds.  
 There are additional avenues that may be considered for future development of adduct-
based exposure markers for HN and other related compounds. First, as mentioned above, 
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quantum mechanical calculations suggest that there may be additional amino acid binding sites 
for these compounds. Future studies with other reactive sites, such as Asp and Glu, may not only 
yield additional potential exposure biomarkers, but may also provide clues regarding the toxic 
mechanism of these compounds. For example, as these two amino acids are found in abundance 
in keratin,87 adduct studies with this protein may provide additional insight into the molecular 
basis of blister agent effects on skin. 
 Second, the current findings may also be directly applicable to the more notorious sulfur 
mustard in terms of potential exposure biomarkers. While HD adduction to His has been 
documented83 to a limited degree, improvements in LC-MS and LC-MS-MS technology since 
these earlier studies may allow for identification of specific adducted residues for this related 
CWA. Finally, while the present work focused on the initial identification of these adducts, the 
conditions utilized for their reliable identification (in particular, the relatively high levels of HN 
required for adduct detection and reproducibility) may be best suited to modeling acute, high-
level as opposed to chronic, low-level exposure. Additional work should be done in which more 
sensitive methods are utilized to lower the detection limit for adduct analysis. For example, 
specific adducted tryptic peptides could be synthesized and utilized for MS and MS-MS 
parameter optimization (such as fragmentor voltage and collision energy). In addition, such 
standards could be used for MRM optimization and detection via QQQ, which would provide a 
level of sensitivity that cannot be achieved with current Q-TOF instrumentation. As detection 
technology becomes more sensitive, these novel protein adducts will have increasing potential as 
exposure biomarkers for these agents at lower exposure levels, potentially to the point at which 
no overt symptoms are present in exposed individuals. These protein adducts could then be 
employed as sensitive, specific, and stable biomarkers of exposure to the nitrogen mustard 
chemical warfare agents HN-2 and HN-3. 
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APPENDICES 
Appendix 1: Biotransformation of Cyclophosphamide 
Compiled based on (a) Colvin, O.M.,108 (b) Hadidi et al.,140 (c) Struck et al.,141 and (d) Yule et al.142  
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Appendix 2: Biotransformation of Chlorambucil 
Compiled based  on (a)Alberts et al.,143 (b) McLean et al., 144 (c) McLean et al., 145 (d) Cullis et 
al., 146 (e) Gunnarsson et al.,147 (f) Hartley-Asp et al.,148 (g) Lee et al.,149 and (h)Pettersson-
Fernholm et al.116   
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Appendix 3: Biotransformation of Melphalan 
Compiled from (a) Stout and Riley,150 (b) Zhang et al.,151 (c) Alaoui-Jamali et al.,46 and (d) Dulik 
et al.152   
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Appendix 4: MS/MS fragmentation of Model Peptides (a) AcPAACAA, (b) AcPAAKAA, and (c) 
AcPAAHAA 
142 
Appendix 5: BioConfirm Data Analysis Parameters for (a) Protein Deconvolution and (b) Protein 
Digest Analysis 
a. Protein Deconvolution Parameters: Deconvolution (MS): Maximum Entropy 
Parameter 
Value 
Hemoglobin Human Serum Albumin 
Mass Range (Da) 10,000 – 17,000  50,000 – 70,000  
Mass Step 1 Da 
Signal-to-Noise Threshold 30 
Adduct Proton 
Average Mass 90% Peak Height 75% Peak Height 
Minimum Consecutive Charge States 5 
Minimum Protein Fit Score 8 
 
b. Protein Digest Analysis:  
Find Compounds by Molecular Feature 
Parameter Value 
m/z Range 350 – 3200 Da 
Positive Ions allowed +H, +Na, +K, +NH4 
Allow for Salt-dominated Positive Ions? Yes 
Target Data Type Small molecules (Chromatographic) 
Peak Filters Use peaks with height ≥ 300 counts 
Isotope Model Peptides 
Charge State Limits Maximum charge state of 4 
Isotope Grouping Peak Space tolerance: 0.0025 m/z, plus 7.0 ppm 
Peak Filters (MS/MS) Limit max number of peaks (by height) to largest 50
Results Reporting 
Extract Avg. MS/MS Spectrum for all CE 
Precursor tolerance: ± 20.00 ppm 
Deisotope MS/MS spectrum 
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Define and Match Sequences: Hemoglobin 
Sequences135,136 
Alpha Subunit:
VLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTKTYFPHFD
LSHGSAQVKGHGKKVADALTNAVAHVDDMPNALSALSDLHAHKLR
VDPVNFKLLSHCLLVTLAAHLPAEFTPAVHASLDKFLASVSTVLTSK 
YR 
 
Beta Subunit: 
VHLTPEEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESRG
DLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSELH
CDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVA
NALAHKYH  
Predicted 
Modification 
Alkylation (Iodoacetamide): +57.021464 
Carbamylation: +43.005184 
Oxidation: +15.994915 
Deamidation: +0.984016 
HN-2 OH: +101.084064 
HN-2 Cl: +119.050177 
HN-3 OH: 131.094629 
HN-3 OH: 149.060742 
Mass Matching MS mass tolerance: ± 10.00 ppm MS/MS mass tolerance: ±50.00 ppm 
Scoring 
MS Score: 30 
MS/MS Score: 70 
(50% MS/MS peak intensity, 50% MS/MS matched ion score) 
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Define and Match Sequences: Human Serum Albumin 
Sequence153 
DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVT
EFAKTCVAESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQ
EPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYE
IARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDE
GKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKL
VTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKP
LLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGM
FLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDE
FKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLV
EVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVS
DRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSE
KERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDK
ETCFAEEGKKLVAASQAALGL 
Predicted 
Modification 
Alkylation (Iodoacetamide): +57.021464 
Carbamylation: +43.005184 
Oxidation: +15.994915 
Deamidation: +0.984016 
HN-2 OH: +101.084064 
HN-2 Cl: +119.050177 
HN-3 OH: 131.094629 
HN-3 OH: 149.060742 
Mass Matching MS mass tolerance: ± 10.00 ppm MS/MS mass tolerance: ±50.00 ppm 
Scoring 
MS Score: 30 
MS/MS Score: 70 
(50% MS/MS peak intensity, 50% MS/MS matched ion score) 
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Appendix 6: LC-MS and LC-MS/MS Parameters 
1. Model Peptide Adduction  and Metabolism Studies  
a. Full Scan (Peptide and Metabolism Studies) 
Parameter Value 
Pump Program 
0.0 – 0.5 min: Hold at 10% B 
0.5 – 5.0 min: Ramp from 10% B to 25% B 
5.0 – 5.5 min: Ramp from 25% B to 95% B 
5.5 – 7.0 min: Hold at 95% B 
Post-Time Equilibration 7 minutes at 10% B 
Solvent Composition A: 0.1% Trifluoroacetic acid (TFA) in HPLC H2O B: 95:5:0.1% Acetonitrile:H2O:TFA 
Flow Rate 0.5 mL/min 
Injection Volume 2.0 μL 
Column Temperature 40.0 °C 
MS Mode MS2 Scan (QQQ) 
MS Parameters Frag: 140 V 
 
b. Product Ion 
Parameter Value 
Pump Program 
0.0 – 0.5 min: Hold at 10% B 
0.5 – 5.0 min: Ramp from 10% B to 25% B 
5.0 – 5.5 min: Ramp from 25% B to 95% B 
5.5 – 7.0 min: Hold at 95% B 
Post-Time Equilibration 7 minutes at 10% B 
Solvent Composition A: 0.1% Trifluoroacetic acid (TFA) in HPLC H2O B: 95:5:0.1% Acetonitrile:H2O:TFA 
Flow Rate 0.5 mL/min 
Injection Volume 2.0 μL 
Column Temperature 40.0 °C 
MS Mode Product Ion (QQQ) 
MS Parameters 
Cys: Precursor Ions: 545, 646, 664, 676, 694 
         Frag 140 V 
         CE: 20 V, 25 V, 30 V 
Lys: Precursor Ions: 570, 671, 689, 701, 719 
         Frag: 140 V 
         CE: 20 V, 30 V, 40 V 
His: Precursor Ions: 579, 680, 698, 710, 728  
        Frag: 140 V 
        CE: 20 V, 30 V, 40 V          
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2. Whole Protein Digest Studies  
Hemoglobin 
Parameter Value 
Pump Program 
0.0 – 0.5 min: Hold at 10% B 
0.5 – 15.0 min: Ramp from 10% B to 60% B 
15.0 – 16.0 min: Ramp from 60% B to 100% B 
16.0 – 21.0 min: Hold at 100% B 
Post-Time Equilibration 7 minutes at 10% B 
Solvent Composition A: 0.1% Trifluoroacetic acid (TFA) in HPLC H2O B: 95:5:0.1% Acetonitrile:H2O:TFA 
Flow Rate 0.5 mL/min 
Injection Volume 3.0 μL 
Column Temperature 40.0 °C 
MS Mode Auto MS/MS (Q-TOF) 
MS Parameters 
Frag: 175 V 
MS Mass range: 100 – 3000 Da 
MS Scan rate: 4 spectra/second 
MS/MS Scan rate: 3 spectra/second 
Isolation Width MS/MS: Medium (~4 amu) 
Collision Energy Ramp: Slope 3.7 
                                         Offset: 2.5 
Excluded Masses: 121.050873 Da ± 100 ppm 
                               922.009798  Da ± 100 ppm 
Precursor Selection: Max Precursors/cycle: 3 
                                  Precursor threshold: ˃ 1000 cts. 
                                  Isotope Model: Peptides 
                                  Active exclusion after 2 spectra 
Charge State Preference: +2, +3, ˃ +3         
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Human Serum Albumin 
Parameter Value 
Pump Program 
0.0 – 0.5 min: Hold at 4% B 
0.5 – 20.0 min: Ramp from 4% B to 48% B 
20.0 – 21.0 min: Ramp from 48% B to 100% B 
21.0 – 25.0 min: Hold at 100% B 
Post-Time Equilibration 7 minutes at 4% B 
Solvent Composition A: 0.1% Trifluoroacetic acid (TFA) in HPLC H2O B: 95:5:0.1% Acetonitrile:H2O:TFA 
Flow Rate 0.5 mL/min 
Injection Volume 3.0 μL 
Column Temperature 40.0 °C 
MS Mode Auto MS/MS (Q-TOF) 
MS Parameters 
Frag: 175 V 
MS Mass range: 100 – 3000 Da 
MS Scan rate: 4 spectra/second 
MS/MS Scan rate: 3 spectra/second 
Isolation Width MS/MS: Medium (~4 amu) 
Collision Energy Ramp: Slope 3.7 
                                         Offset: 2.5 
Excluded Masses: 121.050873 Da ± 100 ppm 
                               922.009798  Da ± 100 ppm 
Precursor Selection: Max Precursors/cycle: 4 
                                  Precursor Threshold: ˃ 1000 cts. 
                                  Isotope Model: Peptides 
                                  Active exclusion after 2 spectra 
Charge State Preference: +2, +3, ˃ +3         
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3. C8 Whole Protein Analysis Studies  
Parameter Value 
Pump Program 
0.0 – 0.5 min: Hold at 10% B 
0.5 – 20.0 min: Ramp from 10% B to 50% B 
20.0 – 25.0 min: Ramp from 50% B to 60% B 
25.0 – 26.0 min: Ramp from 60% B to 95% B 
26.0 – 30.0 min: Hold at 95% B 
Post-Time Equilibration 7 minutes at 4% B 
Solvent Composition A: 0.1% Trifluoroacetic acid (TFA) in HPLC H2O B: 95:5:0.1% Acetonitrile:H2O:TFA 
Flow Rate 0.5 mL/min 
Injection Volume 10.0 μL 
Column Temperature 40.0 °C 
MS Mode MS Mode (Q-TOF) 
MS Parameters 
Frag: 175 V 
MS Mass range: 100 – 3000 Da 
MS Scan rate: 4 spectra/second 
Collision Energy Ramp: Slope 3.7 
                                         Offset: 2.5 
Excluded Masses: 121.050873 Da ± 100 ppm 
                               922.009798  Da ± 100 ppm 
Precursor Selection: Max Precursors/cycle: 4 
                                  Precursor Threshold: ˃ 1000 cts. 
                                  Isotope Model: Peptides 
                                  Active exclusion after 2 spectra 
Charge State Preference: +2, +3, ˃ +3         
 
4. SIM Metabolism Studies  
Parameter Value 
Pump Program 
1.0 – 0.5 min: Hold at 10% B 
0.5 – 5.0 min: Ramp from 10% B to 25% B 
5.0 – 5.5 min: Ramp from 25% B to 95% B 
5.5 – 7.0 min: Hold at 95% B 
Post-Time Equilibration 7 minutes at 10% B 
Solvent Composition A: 0.1% Trifluoroacetic acid (TFA) in HPLC H2O B: 95:5:0.1% Acetonitrile:H2O:TFA 
Flow Rate 0.5 mL/min 
Injection Volume 2.0 μL 
Column Temperature 40.0 °C 
MS Mode Product Ion (QQQ) 
MS Parameters 
Frag (all): 140 V 
Cys: SIM Ions: 646, 664, 676, 694 
Lys: SIM Ions: 671, 689, 701, 719 
His: SIM Ions: 680, 698, 710, 728  
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Appendix 7: Protein Prospector Data Analysis Parameters 
 
Available online at http://www.prospector/ucsf.edu/prospector/mshome/htm 
Version of software utilized at completion of project: v 5.10.15 
MS-Product Program utilized for labeling of tryptic peptide MS-MS fragments  
Parameter Value 
Sequence 
Based on hypothesized match done by BioConfirm Software. 
 
Iodoacetamide Alkylation represented by PSI notation “Carbamidomethyl”. 
 
HN modification represented by parenthesis followed by exact mass of 
modification (as seen in Appendix 5) 
N-term Sequence a, b 
C-term Sequence x, y 
Internal Fragment Allow for Internal Fragmentation 
Neutral-loss 
Sequence 
-H2O (S, T, E, D) 
-NH3 (R, K, Q, N) 
Peeling Sequence b + H2O (R, H, K) 
Max Charge 2 
Instrument ESI-Q-TOF 
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Appendix 8: Components of Protease Inhibitor Cocktail 
Purchased from Sigma-Aldrich, Catalog Number: P8340 
 
Figure for Aprotinin obtained from Yang et al.154  
Components are removed prior to trypsin digestion via 10 kDa spin filters. 
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Appendix 9: Calculated Reactivity Index Data for HN-2 and HN-3 Electrophilic Intermediates  
 
Note: As it is expected that the aziridinium species are those responsible for adduction, data was 
only calculated for these intermediates. Cys, Lys, and His data have been highlighted in red for 
comparison purposes. 
Electrophile: HN-2 Az OH 
Amino Acid (Charge) Reactivity Index (ω
-) 
(eV) 
Serine (-1) 2.660377271 
Threonine (-1) 2.604330541 
Cysteine (-1) 2.46414707 
Aspartic Acid (-1) 2.137008716 
Glutamic Acid (-1) 1.910437929 
Tryptophan (0) 0.602879711 
Tyrosine (0) 0.594932818 
Arginine (0) 0.556125457 
Lysine (0) 0.541671492 
Asparagine (0) 0.529160347 
Threonine (0) 0.519029658 
Glutamine (0) 0.516742297 
Histidine (0) 0.515973467 
Serine (0) 0.513658011 
Glutamic Acid (0) 0.472297531 
Aspartic Acid (0) 0.45104694 
Cysteine (0) 0.424372333 
Arginine (1) 0.014942882 
Lysine (1) 0.008672125 
Histidine (1) 0.002468309 
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Electrophile: HN-3 Az OH OH 
Amino Acid 
(Charge) 
Reactivity Index 
(ω-) (eV) 
Serine (-1) 2.743354059 
Threonine (-1) 2.684758899 
Cysteine (-1) 2.5417167 
Aspartic Acid (-1) 2.201480744 
Glutamic Acid (-1) 1.973955994 
Tryptophan (0) 0.615134425 
Tyrosine (0) 0.606129284 
Arginine (0) 0.565856589 
Lysine (0) 0.550613803 
Asparagine (0) 0.537226337 
Threonine (0) 0.527228875 
Histidine (0) 0.525503578 
Glutamine (0) 0.524699006 
Serine (0) 0.521675972 
Glutamic Acid (0) 0.479097983 
Aspartic Acid (0) 0.457599431 
Cysteine (0) 0.429982528 
Arginine (1) 0.014074194 
Lysine (1) 0.007937744 
Histidine (1) 0.003189918 
 
Electrophile: HN-3 Az OH Cl 
Amino Acid 
(Charge) 
Reactivity Index 
(ω-) (eV) 
Serine (-1) 3.188096357 
Threonine (-1) 3.121836274 
Cysteine (-1) 2.964150359 
Aspartic Acid (-1) 2.580587256 
Glutamic Acid (-1) 2.330777185 
Tryptophan (0) 0.775460515 
Tyrosine (0) 0.764114282 
Arginine (0) 0.716775779 
Lysine (0) 0.698446552 
Asparagine (0) 0.681936331 
Threonine (0) 0.670957056 
Histidine (0) 0.67075383 
Glutamine (0) 0.667702212 
Serine (0) 0.664411073 
Glutamic Acid (0) 0.614377979 
Aspartic Acid (0) 0.589661246 
Cysteine (0) 0.556747799 
Arginine (1) 0.03664921 
Lysine (1) 0.025686349 
Histidine (1) 0.000108479 
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